{"T3": {"n": 3, "t": "Obstetrics & Gynaecology", "d": "Sep 25 2026", "q": [{"n": 1, "s": "A 26-year-old G1P0 at 20 weeks gestation presents with painless fresh vaginal bleeding. She is Rh-negative and her partner is Rh-positive. Ultrasound confirms a live fetus with no obvious cause for the bleed. Within what time window must anti-D immunoglobulin be administered?", "o": [["A", "24 hours"], ["B", "48 hours"], ["C", "72 hours"], ["D", "96 hours"]], "c": ["C)", "72 hours"], "co": "Anti-D prophylaxis — timing after a sensitising event in pregnancy", "ct": "Recall", "w": "Any potentially sensitising event in an Rh-negative unsensitised woman (here, antepartum bleeding at 20 weeks with an Rh-positive partner) requires anti-D immunoglobulin within 72 hours of the event to prevent maternal sensitisation.", "d": "Rh-negative + antepartum bleeding at 20 weeks = sensitising event → anti-D within 72 hours (not 24, 48, or 96)", "t": "Unit/Number — the only correct window is 72 hours (24/48/96 are the traps)", "f": "Every Rh-negative antenatal bleed = anti-D within 72 hours; also give the routine 28-week dose and postpartum if the baby is Rh-positive", "r": "Rh-negative + sensitising event (APH, pregnancy loss ≥12 weeks, instrumentation) → anti-D within 72 hours", "x": [["A) 24 hours", "24 hours is unnecessarily tight — anti-D must be given within 72 hours of the event, not 24."], ["B) 48 hours", "48 hours is within the window but is not the defined standard; 72 hours is the maximum allowed and the expected answer."], ["D) 96 hours", "96 hours exceeds the 72-hour window — this is the classic wrong option the examiner sets."]]}, {"n": 2, "s": "A 22-year-old primigravida at 10 weeks has been vomiting several times daily for 3 weeks, with 4 kg weight loss and ketonuria. She is dehydrated and being admitted for intravenous fluids. Which of the following should be given BEFORE any intravenous dextrose?", "o": [["A", "Intravenous thiamine"], ["B", "Oral doxylamine"], ["C", "Intravenous potassium"], ["D", "Prochlorperazine suppository"]], "c": ["A)", "Intravenous thiamine"], "co": "Hyperemesis gravidarum — thiamine before dextrose (Wernicke prophylaxis)", "ct": "Analysis/synthesis", "w": "In hyperemesis gravidarum, thiamine must be given before any glucose load because the carbohydrate load can precipitate Wernicke encephalopathy in a thiamine-depleted patient.", "d": "Hyperemesis + IV dextrose → thiamine first to prevent Wernicke encephalopathy", "t": "Iatrogenic trap — dextrose before thiamine precipitates Wernicke encephalopathy in hyperemesis", "f": "Hyperemesis: rehydrate + thiamine first, then dextrose; watch for hypokalaemia and metabolic alkalosis", "r": "Hyperemesis admission → IV thiamine before any dextrose-containing fluid", "x": [["B) Oral doxylamine", "Doxylamine (with pyridoxine) is a first-line oral antiemetic, but it does not protect against Wernicke encephalopathy."], ["C) Intravenous potassium", "Potassium replacement may be needed, but it is not the priority before glucose."], ["D) Prochlorperazine suppository", "Prochlorperazine is symptomatic; it does not address the thiamine-dextrose interaction."]]}, {"n": 3, "s": "A 27-year-old woman with a BMI of 32 kg/m² and a first-degree relative with diabetes is at 26 weeks gestation; her fasting glucose was normal at booking. Which test is most appropriate for screening for gestational diabetes?", "o": [["A", "Random blood glucose"], ["B", "HbA1c"], ["C", "75 g oral glucose tolerance test (OGTT)"], ["D", "Urine dipstick for glucose"]], "c": ["C)", "75 g oral glucose tolerance test (OGTT)"], "co": "Gestational diabetes — screening and diagnostic test", "ct": "Recall", "w": "The gold standard for gestational diabetes screening and diagnosis is the 75 g oral glucose tolerance test performed at 24-28 weeks; random glucose and HbA1c are not validated for GDM.", "d": "GDM screening/diagnosis = 75 g OGTT at 24-28 weeks; random glucose and HbA1c are not validated in pregnancy", "t": "Investigation hierarchy — the 75 g OGTT is the GDM diagnostic standard, not random glucose or HbA1c", "f": "GDM = 75 g OGTT at 24-28 weeks; women with prior GDM are screened earlier in pregnancy", "r": "GDM screening at 24-28 weeks → 75 g OGTT (fasting, 1-hour, 2-hour values)", "x": [["A) Random blood glucose", "Random glucose lacks sensitivity and specificity for GDM and is not validated for diagnosis."], ["B) HbA1c", "HbA1c underestimates pregnancy-specific dysglycaemia and is not a GDM diagnostic tool."], ["D) Urine dipstick for glucose", "Glycosuria is common in normal pregnancy and is not diagnostic."]]}, {"n": 4, "s": "A 24-year-old primigravida at 35 weeks presents with headache and a blood pressure of 172/112 mmHg confirmed on two readings 15 minutes apart, with 3+ proteinuria. Which medication is most appropriate for immediate blood pressure control?", "o": [["A", "IV labetalol"], ["B", "Oral methyldopa"], ["C", "Oral enalapril"], ["D", "IV hydralazine"]], "c": ["A)", "IV labetalol"], "co": "Severe pre-eclampsia — first-line antihypertensive (labetalol)", "ct": "Interpretation (BP threshold + drug selection)", "w": "Severe pre-eclampsia with BP ≥160/110 mmHg requires prompt parenteral control; IV labetalol is the first-line agent. ACE inhibitors are absolutely contraindicated in pregnancy and methyldopa works too slowly for an acute hypertensive emergency.", "d": "BP ≥160/110 + proteinuria = severe pre-eclampsia → IV labetalol first-line; ACE inhibitors are fetotoxic and methyldopa acts too slowly", "t": "Treatment misdirection — 'any antihypertensive' fails: enalapril is fetotoxic and methyldopa is too slow for acute severe hypertension", "f": "Labetalol first-line for acute severe BP in pregnancy; ACEi/ARBs NEVER; methyldopa is chronic oral therapy", "r": "Severe BP in pre-eclampsia → IV labetalol first-line; ACEi/ARBs contraindicated", "x": [["B) Oral methyldopa", "Methyldopa is a useful oral agent for chronic control but has a slow onset — inadequate for acute severe hypertension."], ["C) Oral enalapril", "Enalapril (ACE inhibitor) is fetotoxic (fetal renal impairment, oligohydramnios) and absolutely contraindicated in pregnancy."], ["D) IV hydralazine", "IV hydralazine is a second-line option with more maternal side effects; labetalol is the first-line answer."]]}, {"n": 5, "s": "A 25-year-old G1P0 at term has a prolonged second stage of labour. The fetal head is vertex at +2 station. Which of the following findings would PREVENT instrumental (vacuum or forceps) vaginal delivery?", "o": [["A", "Incomplete cervical dilation"], ["B", "Epidural anaesthesia in place"], ["C", "Empty maternal bladder"], ["D", "Ruptured membranes"]], "c": ["A)", "Incomplete cervical dilation"], "co": "Instrumental delivery — absolute prerequisites and contraindications", "ct": "Interpretation", "w": "Instrumental vaginal delivery requires full cervical dilation, ruptured membranes, an engaged vertex (or known presentation), and an empty bladder. Incomplete dilation is an absolute contraindication.", "d": "Full cervical dilation is an absolute prerequisite for instrumental delivery, along with an engaged head and ruptured membranes", "t": "Partial Truth — full dilation is an absolute prerequisite; 'almost fully dilated' is not acceptable", "f": "Instrumental delivery checklist: full dilation + engaged head + ruptured membranes + empty bladder + consent + skilled operator", "r": "No instrumental delivery without full dilation, engaged head, and ruptured membranes", "x": [["B) Epidural anaesthesia in place", "Epidural anaesthesia is not a contraindication — it often facilitates instrumental delivery."], ["C) Empty maternal bladder", "An empty bladder is a prerequisite, not a barrier — a full bladder is what prevents delivery."], ["D) Ruptured membranes", "Ruptured membranes are required, not a barrier."]]}, {"n": 6, "s": "A 29-year-old primigravida at term in established labour is receiving an oxytocin infusion. The CTG shows uniform decelerations that begin after the peak of each contraction and return slowly to baseline, with reduced baseline variability. Contractions are every 2 minutes. What is the single most appropriate first action?", "o": [["A", "Stop the oxytocin infusion and reposition the woman left lateral with oxygen"], ["B", "Increase the oxytocin infusion rate"], ["C", "Proceed directly to emergency caesarean section"], ["D", "Perform artificial rupture of membranes"]], "c": ["A)", "Stop the oxytocin infusion and reposition the woman left lateral with oxygen"], "co": "Intrapartum fetal monitoring — late decelerations (uteroplacental insufficiency)", "ct": "Analysis/synthesis (CTG pattern + escalation logic)", "w": "Late decelerations indicate uteroplacental insufficiency; with an oxytocin infusion running, the first action is to stop the infusion and reposition the mother (left lateral) with oxygen, then reassess fetal status before deciding on delivery.", "d": "Late decelerations + reduced variability + oxytocin running = uteroplacental insufficiency → stop oxytocin, left lateral, oxygen, reassess", "t": "Pattern recognition — late decelerations = uteroplacental insufficiency, not cord or head compression", "f": "Late decels = placenta; variable decels = cord; early decels = head; escalate oxytocin only with a reassuring tracing", "r": "Late decelerations + reduced variability → stop oxytocin, left lateral, maternal oxygen, reassess (intrauterine resuscitation)", "x": [["B) Increase the oxytocin infusion rate", "Increasing oxytocin augments contractions and worsens uteroplacental insufficiency — the opposite of what is needed."], ["C) Proceed directly to emergency caesarean section", "Caesarean is decided only after intrauterine resuscitation fails or the tracing remains pathological; it is not the first action."], ["D) Perform artificial rupture of membranes", "Amniotomy does not correct uteroplacental insufficiency and may further compromise the fetus."]]}, {"n": 7, "s": "A 28-year-old G2P1 at 37 weeks had a positive group B streptococcus (GBS) vaginal swab at 36 weeks. She is now in labour with ruptured membranes for 2 hours and is asymptomatic — no fever and no uterine tenderness. What is the most appropriate management?", "o": [["A", "Intravenous benzylpenicillin during labour"], ["B", "A 7-day course of oral amoxicillin at home"], ["C", "No treatment — she is asymptomatic"], ["D", "Vaginal clotrimazole pessaries"]], "c": ["A)", "Intravenous benzylpenicillin during labour"], "co": "Group B streptococcus — intrapartum antibiotic prophylaxis", "ct": "Interpretation", "w": "Known GBS carriage with labour or rupture of membranes is an indication for intrapartum intravenous antibiotic prophylaxis (benzylpenicillin) to prevent early-onset neonatal GBS disease — maternal symptoms are irrelevant.", "d": "GBS carrier + labour/ROM → intrapartum IV penicillin regardless of maternal symptoms (protects the neonate)", "t": "Negative discrimination — 'asymptomatic = no prophylaxis' is wrong; GBS prophylaxis protects the neonate", "f": "GBS + labour = IV penicillin intrapartum; oral therapy does not eradicate vaginal carriage; check for ROM >18 h, fever, prior GBS baby", "r": "GBS colonisation + labour/ROM → intrapartum IV benzylpenicillin (or ampicillin) q4h until delivery", "x": [["B) A 7-day course of oral amoxicillin at home", "Oral antibiotics do not reliably clear lower genital tract colonisation and do not give adequate intrapartum neonatal protection."], ["C) No treatment — she is asymptomatic", "Prophylaxis is indicated purely on carriage + labour, independent of maternal symptoms."], ["D) Vaginal clotrimazole pessaries", "Clotrimazole treats candidiasis, not GBS carriage."]]}, {"n": 8, "s": "A 28-year-old G2P1 at 30 weeks is in established preterm labour with the cervix 5 cm dilated; delivery is expected within hours. Betamethasone has been given. Why is magnesium sulfate being administered at this point?", "o": [["A", "Fetal neuroprotection (reducing cerebral palsy risk)"], ["B", "Tocolytic therapy to stop contractions"], ["C", "Prophylaxis against eclampsia"], ["D", "Uterine relaxation before external cephalic version"]], "c": ["A)", "Fetal neuroprotection (reducing cerebral palsy risk)"], "co": "Preterm labour — magnesium sulfate for fetal neuroprotection", "ct": "Recall/interpretation", "w": "When preterm birth before 32 weeks is imminent, magnesium sulfate is given for fetal neuroprotection — it reduces the risk of cerebral palsy. It is not used here as a tocolytic or for eclampsia prophylaxis.", "d": "Imminent preterm birth <32 weeks → magnesium sulfate is neuroprotective (reduces cerebral palsy), distinct from its use in eclampsia", "t": "Treatment misdirection — magnesium here is fetal neuroprotection, not tocolysis or eclampsia prophylaxis", "f": "MgSO4 in preterm labour = neuroprotection (<32 weeks, delivery imminent); MgSO4 in pre-eclampsia = seizure prophylaxis", "r": "Imminent preterm birth <32 weeks → MgSO4 for fetal neuroprotection (cerebral palsy risk reduction), not tocolysis", "x": [["B) Tocolytic therapy to stop contractions", "Magnesium is not an effective tocolytic — nifedipine or atosiban fills that role."], ["C) Prophylaxis against eclampsia", "Eclampsia prophylaxis applies to pre-eclampsia, not preterm labour in a normotensive woman."], ["D) Uterine relaxation before external cephalic version", "Magnesium is not used for external cephalic version."]]}, {"n": 9, "s": "A 38-year-old G1P0 at 12 weeks gestation has a first-trimester combined screening result indicating high risk of trisomy 21, and requests definitive prenatal diagnosis. Which procedure is most appropriate at this gestation?", "o": [["A", "Chorionic villus sampling (CVS)"], ["B", "Amniocentesis"], ["C", "Cordocentesis"], ["D", "Non-invasive prenatal testing (NIPT) alone"]], "c": ["A)", "Chorionic villus sampling (CVS)"], "co": "Prenatal diagnosis — CVS timing (10-13 weeks) vs amniocentesis (15-20 weeks)", "ct": "Recall/interpretation", "w": "Definitive karyotyping at 12 weeks is achieved by chorionic villus sampling (10-13 weeks); amniocentesis for karyotype is performed from 15-20 weeks, so it is not yet possible here.", "d": "At 12 weeks, karyotype requires CVS (10-13 weeks); amniocentesis is performed at 15-20 weeks", "t": "Synonym Swap — CVS at 10-13 weeks vs amniocentesis at 15-20 weeks", "f": "First trimester (10-13 weeks) = CVS; second trimester (15-20 weeks) = amniocentesis; NIPT is screening, not diagnostic", "r": "Karyotype at 10-13 weeks → CVS; at ≥15 weeks → amniocentesis", "x": [["B) Amniocentesis", "Amniocentesis is performed at 15-20 weeks — not yet possible at 12 weeks."], ["C) Cordocentesis", "Cordocentesis is a later second/third-trimester procedure used for specific haematological indications."], ["D) Non-invasive prenatal testing (NIPT) alone", "NIPT is a screening test, not a definitive diagnostic test."]]}, {"n": 10, "s": "A 29-year-old G2P1 at 32 weeks presents with intense itching, worst at night and affecting the palms and soles, for 2 weeks. There is no rash, and liver transaminases are normal. Fasting serum bile acids are 40 µmol/L. What is the most likely diagnosis?", "o": [["A", "Intrahepatic cholestasis of pregnancy"], ["B", "Acute fatty liver of pregnancy"], ["C", "HELLP syndrome"], ["D", "Polymorphic eruption of pregnancy (PUPPP)"]], "c": ["A)", "Intrahepatic cholestasis of pregnancy"], "co": "Intrahepatic cholestasis of pregnancy — diagnosis", "ct": "Interpretation", "w": "Intractable pruritus without a rash in the third trimester with elevated fasting serum bile acids is intrahepatic cholestasis of pregnancy; transaminases may be normal or mildly raised.", "d": "Pruritus WITHOUT rash + raised bile acids + normal transaminases = obstetric cholestasis", "t": "Clinical Mimic — itch-without-rash + raised bile acids = ICP, not PUPPP or urticaria", "f": "Itch + raised bile acids = ICP → UDCA + monitoring + delivery planning (~37-38 weeks); normal LFTs/platelets exclude AFLP/HELLP", "r": "Pruritus without rash + fasting bile acids ≥10 µmol/L = intrahepatic cholestasis of pregnancy", "x": [["B) Acute fatty liver of pregnancy", "AFLP presents with systemic illness (jaundice, hypoglycaemia, coagulopathy), not isolated pruritus."], ["C) HELLP syndrome", "HELLP features haemolysis, thrombocytopenia, and transaminitis — absent here."], ["D) Polymorphic eruption of pregnancy (PUPPP)", "PUPPP is a rash with itching — this woman has no rash."]]}, {"n": 11, "s": "A 34-year-old woman has an uncomplicated monochorionic diamniotic (MCDA) twin pregnancy at 34 weeks. When is planned delivery recommended for uncomplicated monochorionic diamniotic twins?", "o": [["A", "36-37 weeks"], ["B", "32-33 weeks"], ["C", "40 weeks"], ["D", "34-35 weeks"]], "c": ["A)", "36-37 weeks"], "co": "Multiple pregnancy — delivery timing by chorionicity", "ct": "Interpretation (chorionicity-based delivery timing)", "w": "For uncomplicated monochorionic diamniotic twins, planned delivery is recommended at 36-37 weeks because of the shared placenta and rising late-stillbirth risk; dichorionic twins are allowed to 37-38 weeks.", "d": "Uncomplicated MCDA twins deliver at 36-37 weeks (shared placenta); dichorionic twins at 37-38 weeks", "t": "Age-appropriate differential — gestational-age delivery windows differ by chorionicity (MCDA 36-37 weeks)", "f": "Chorionicity sets the clock: MCDA 36-37 weeks, DCDA 37-38 weeks; monoamniotic monochorionic twins deliver much earlier (32-34 weeks)", "r": "Uncomplicated MCDA twins → plan delivery at 36-37 weeks; DCDA → 37-38 weeks", "x": [["B) 32-33 weeks", "32-33 weeks is the window for monochorionic MONOamniotic twins, not MCDA."], ["C) 40 weeks", "40 weeks carries an unacceptable late-stillbirth risk for any twin pregnancy, especially monochorionic."], ["D) 34-35 weeks", "34-35 weeks is earlier than recommended for uncomplicated MCDA twins."]]}, {"n": 12, "s": "A 27-year-old primigravida in established labour has a partograph whose cervicometric progress line has crossed the action line. Contractions are irregular and weak, and the fetal heart is reassuring. What is the most appropriate next step?", "o": [["A", "Oxytocin augmentation"], ["B", "Immediate caesarean section"], ["C", "Continue expectant monitoring for another 4 hours"], ["D", "Vacuum-assisted delivery"]], "c": ["A)", "Oxytocin augmentation"], "co": "Progress of labour — partograph action line and augmentation", "ct": "Interpretation", "w": "Crossing the partograph action line in the presence of inadequate contractions and a reassuring fetal heart indicates delay from uterine dysfunction — oxytocin augmentation is the standard intervention.", "d": "Progress line crossing the action line with inadequate contractions + reassuring FHR → oxytocin augmentation, not caesarean", "t": "Overthinking — a crossed action line triggers oxytocin augmentation, not immediate caesarean", "f": "Partograph: alert line = warn; action line = act (augment); caesarean is for obstruction or fetal compromise", "r": "Action line crossed + weak contractions + reassuring FHR → oxytocin augmentation (after ruling out obstruction)", "x": [["B) Immediate caesarean section", "Caesarean is reserved for obstruction, fetal compromise, or failed augmentation — not first-line for a crossed action line alone."], ["C) Continue expectant monitoring for another 4 hours", "Further expectant monitoring delays treatment of established delay."], ["D) Vacuum-assisted delivery", "Vacuum delivery is for the second stage, not first-stage delay."]]}, {"n": 13, "s": "A 36-year-old G6P5 (grand multipara) in labour at term for 16 hours develops sudden severe constant suprapubic pain. Contractions have stopped and the fetal heart rate is 90 bpm. The abdomen is tender with a distended lower segment, and on vaginal examination the presenting part, previously engaged, is no longer felt. What is the most likely diagnosis and management?", "o": [["A", "Uterine rupture — immediate laparotomy"], ["B", "Cord prolapse — elevate the presenting part"], ["C", "Placental abruption — expectant vaginal delivery"], ["D", "Bandl's ring — wait for spontaneous resolution"]], "c": ["A)", "Uterine rupture — immediate laparotomy"], "co": "Uterine rupture in obstructed labour (unscarred uterus) — diagnosis and management", "ct": "Analysis/synthesis (diagnosis + emergency management)", "w": "In a grand multipara with obstructed labour, sudden cessation of contractions, loss of the presenting part, and fetal bradycardia indicate uterine rupture — an emergency requiring immediate laparotomy.", "d": "Grand multipara + obstructed labour + loss of station + fetal bradycardia = uterine rupture → immediate laparotomy", "t": "Severity under-recognition — constant pain + lost station = uterine rupture, not slow progress", "f": "Uterine rupture triad: obstructed/ scarred uterus + sudden pain + fetal distress/lost station → laparotomy now", "r": "Obstructed labour + lost station + fetal bradycardia = uterine rupture → immediate laparotomy", "x": [["B) Cord prolapse — elevate the presenting part", "Cord prolapse would show the cord on examination, not a lost presenting part."], ["C) Placental abruption — expectant vaginal delivery", "Abruption features a tender woody uterus with bleeding, not loss of the presenting part."], ["D) Bandl's ring — wait for spontaneous resolution", "Bandl's ring (pathological retraction ring) signals impending rather than established rupture and never resolves spontaneously."]]}, {"n": 14, "s": "A 23-year-old G2P1 at 31 weeks presents with preterm prelabour rupture of membranes. She is not in labour, the fetus is well, and there are no signs of chorioamnionitis. Corticosteroids have been given. Which additional management is most appropriate?", "o": [["A", "Oral erythromycin for 10 days (latency antibiotics)"], ["B", "Oral co-amoxiclav for 10 days"], ["C", "No antibiotics unless fever develops"], ["D", "Immediate elective caesarean section"]], "c": ["A)", "Oral erythromycin for 10 days (latency antibiotics)"], "co": "PPROM — latency antibiotics (erythromycin)", "ct": "Interpretation", "w": "In PPROM before 34 weeks without chorioamnionitis, oral erythromycin for 10 days prolongs latency and reduces neonatal infection; co-amoxiclav is avoided because of its association with neonatal necrotising enterocolitis.", "d": "PPROM <34 weeks without chorioamnionitis → oral erythromycin 10 days prolongs latency; co-amoxiclav is associated with NEC", "t": "Treatment misdirection — co-amoxiclav is linked to NEC in PPROM; erythromycin is the latency antibiotic", "f": "PPROM <34 weeks: steroids + erythromycin 10 days; avoid co-amoxiclav (NEC); fever/tenderness = chorioamnionitis, deliver", "r": "PPROM <34 weeks, no chorioamnionitis → latency antibiotics: oral erythromycin 10 days + antenatal corticosteroids", "x": [["B) Oral co-amoxiclav for 10 days", "Co-amoxiclav is avoided in PPROM because of its association with neonatal necrotising enterocolitis."], ["C) No antibiotics unless fever develops", "Antibiotics are given proactively for latency even without fever — this is prophylaxis, not treatment of established infection."], ["D) Immediate elective caesarean section", "Expectant management with latency antibiotics and steroids is standard; immediate delivery is not indicated without infection or fetal compromise."]]}, {"n": 15, "s": "During a vaginal delivery at 39 weeks of a 4.2 kg baby, the head delivers but the anterior shoulder remains impacted behind the symphysis pubis (turtle sign). McRoberts manoeuvre and suprapubic pressure have failed. Which of the following is contraindicated in this situation?", "o": [["A", "Fundal pressure"], ["B", "Delivery of the posterior arm"], ["C", "Wood's corkscrew (rotational) manoeuvre"], ["D", "All-fours position with continued suprapubic pressure"]], "c": ["A)", "Fundal pressure"], "co": "Shoulder dystocia — what NOT to do (fundal pressure)", "ct": "Analysis/synthesis (emergency sequencing + safety)", "w": "Fundal pressure is contraindicated in shoulder dystocia — it can worsen shoulder impaction and cause fetal brachial plexus injury and fractures. The HELPERR sequence (McRoberts, suprapubic pressure, internal manoeuvres) is used instead.", "d": "Shoulder dystocia management excludes fundal pressure, which further impacts the shoulder and risks fetal injury", "t": "'What NOT to do' — fundal pressure worsens shoulder impaction and is forbidden in shoulder dystocia", "f": "Shoulder dystocia = McRoberts + suprapubic pressure → posterior arm/internal rotation; NEVER fundal pressure", "r": "Shoulder dystocia: McRoberts + suprapubic pressure first; fundal pressure is always contraindicated", "x": [["B) Delivery of the posterior arm", "Delivery of the posterior arm is a recognised step when the initial manoeuvres fail."], ["C) Wood's corkscrew (rotational) manoeuvre", "Wood's corkscrew (rotational) manoeuvre is a standard internal manoeuvre."], ["D) All-fours position with continued suprapubic pressure", "The all-fours position is part of the escalation sequence and helps with posterior shoulder delivery."]]}, {"n": 16, "s": "A 24-year-old with severe pre-eclampsia at 34 weeks receives the standard 4 g intravenous magnesium sulfate loading dose. Which maintenance infusion rate is most appropriate?", "o": [["A", "0.5 g/hour"], ["B", "1 g/hour"], ["C", "2 g/hour"], ["D", "4 g/hour"]], "c": ["B)", "1 g/hour"], "co": "Magnesium sulfate — maintenance infusion rate", "ct": "Recall", "w": "The standard regimen is a 4 g IV loading dose over 5 minutes followed by a maintenance infusion of 1 g/hour (Pritchard regimen), continued for 24 hours after delivery or the last seizure.", "d": "After the 4 g IV load, magnesium maintenance infusion runs at 1 g/hour", "t": "Unit/Number — maintenance runs at 1 g/h, not the 4 g load or 0.5/2 g/h", "f": "MgSO4: 4 g load then 1 g/h maintenance; monitor DTRs, respiratory rate, urine output; antidote = IV calcium gluconate", "r": "MgSO4 regimen = 4 g IV load + 1 g/h maintenance; stop for oliguria, RR <12, or absent DTRs", "x": [["A) 0.5 g/hour", "0.5 g/hour is too low to maintain a therapeutic level."], ["C) 2 g/hour", "2 g/hour exceeds the standard maintenance rate (reserved for refractory protocols only)."], ["D) 4 g/hour", "4 g/hour is the loading dose, not a maintenance rate."]]}, {"n": 17, "s": "A 28-year-old G2P1 at 37 weeks with an uncomplicated pregnancy has a CTG that shows a smooth, regular, sine-wave pattern of the fetal heart rate at 130 bpm with no beat-to-beat variability. Which condition is most likely to be associated with this pattern?", "o": [["A", "Severe fetal anaemia"], ["B", "Fetal sleep"], ["C", "Cord compression"], ["D", "Normal fetal behaviour"]], "c": ["A)", "Severe fetal anaemia"], "co": "Sinusoidal CTG pattern — fetal anaemia", "ct": "Interpretation", "w": "A true sinusoidal CTG pattern (smooth sine-wave oscillations with absent variability) is an ominous pattern classically associated with severe fetal anaemia, such as Rh isoimmunisation or feto-maternal haemorrhage.", "d": "Smooth sine-wave FHR with absent variability = sinusoidal pattern → fetal anaemia (feto-maternal haemorrhage, Rh disease)", "t": "Pattern recognition — sinusoidal rhythm signals fetal anaemia, an ominous not reassuring pattern", "f": "Sinusoidal CTG = fetal anaemia → urgent evaluation (MCA Doppler, delivery planning), never reassure", "r": "Sinusoidal FHR pattern → suspect severe fetal anaemia; investigate and plan delivery", "x": [["B) Fetal sleep", "Fetal sleep causes reduced variability, not a fixed sinusoidal waveform."], ["C) Cord compression", "Cord compression produces variable decelerations, not a sinusoidal pattern."], ["D) Normal fetal behaviour", "Sinusoidal rhythm is pathological, never a normal fetal behaviour pattern."]]}, {"n": 18, "s": "A 28-year-old primigravida in labour at term has a vaginal examination that reveals a face presentation with the chin (mentum) directed posteriorly. The cervix is 8 cm dilated and the fetal heart is reassuring. What is the most appropriate management?", "o": [["A", "Planned caesarean section"], ["B", "Forceps rotation of the face"], ["C", "Allow labour to continue — vaginal delivery is expected"], ["D", "Manual rotation to mentum anterior"]], "c": ["A)", "Planned caesarean section"], "co": "Face presentation — mentum posterior requires caesarean", "ct": "Interpretation", "w": "In face presentation, mentum anterior can deliver vaginally, but mentum posterior cannot engage because the head cannot flex — caesarean section is required.", "d": "Face + mentum posterior cannot engage/flex → caesarean; mentum anterior can deliver vaginally", "t": "Opposite — mentum anterior delivers vaginally; mentum posterior does not", "f": "Face presentation: check mentum direction — anterior = vaginal, posterior = CS; forceps rotation is dangerous", "r": "Mentum posterior face presentation → caesarean section; mentum anterior → vaginal delivery possible", "x": [["B) Forceps rotation of the face", "Forceps rotation of a face presentation is dangerous and is not conventional delivery practice."], ["C) Allow labour to continue — vaginal delivery is expected", "Mentum posterior cannot deliver vaginally — the head remains deflexed and fails to engage."], ["D) Manual rotation to mentum anterior", "Manual rotation of a deflexed face is not a standard or safe manoeuvre."]]}, {"n": 19, "s": "A 30-year-old G2P1 is in active labour. Immediately after spontaneous rupture of membranes, the umbilical cord is seen at the introitus and the fetal heart rate drops to 60 bpm. The cervix is fully dilated and the vertex is at +2 station with no caput. What is the most appropriate management?", "o": [["A", "Immediate assisted vaginal delivery (vacuum or forceps)"], ["B", "Emergency caesarean section"], ["C", "Manual replacement of the cord with oxytocin augmentation"], ["D", "Transfer to theatre with CTG monitoring only"]], "c": ["A)", "Immediate assisted vaginal delivery (vacuum or forceps)"], "co": "Cord prolapse at full dilatation — expedited vaginal delivery", "ct": "Analysis/synthesis (emergency delivery decision)", "w": "In cord prolapse the priority is immediate delivery. At full cervical dilatation with the vertex at +2, assisted vaginal delivery (vacuum or forceps) is the faster and correct choice; caesarean is reserved for when vaginal delivery is not immediately possible.", "d": "Cord prolapse + FULL dilation + engaged vertex → assisted vaginal delivery; caesarean is for incomplete dilatation", "t": "Treatment misdirection — at full dilation, assisted vaginal delivery replaces the caesarean reflex of cord prolapse", "f": "Cord prolapse: full dilation + engaged head = expedite vaginally; not fully dilated = lift head off cord + emergency CS", "r": "Cord prolapse at full dilation with engaged vertex → immediate assisted vaginal delivery; CS if not fully dilated", "x": [["B) Emergency caesarean section", "Caesarean is for cord prolapse with incomplete dilation — at full dilation the faster route is assisted vaginal delivery."], ["C) Manual replacement of the cord with oxytocin augmentation", "Replacing the cord and augmenting labour wastes time in acute fetal compromise."], ["D) Transfer to theatre with CTG monitoring only", "Monitoring alone does nothing to relieve cord compression or expedite delivery."]]}, {"n": 20, "s": "A 29-year-old G2P1 at 16 weeks undergoes an ultrasound that reports suboptimal fetal cardiac views. When is the optimally timed detailed fetal anomaly scan performed?", "o": [["A", "11-13 weeks"], ["B", "16-17 weeks"], ["C", "18-22 weeks"], ["D", "22-24 weeks"]], "c": ["C)", "18-22 weeks"], "co": "Antenatal screening — timing of the fetal anomaly scan", "ct": "Recall", "w": "The detailed fetal anomaly scan is optimally performed at 18-22 weeks gestation, when fetal anatomy, particularly the heart, can be fully evaluated.", "d": "Detailed anomaly scan = 18-22 weeks; 11-13 weeks is the nuchal translucency scan, and 16-17 weeks gives incomplete views", "t": "Guideline Version — the anomaly scan window is 18-22 weeks, not 16-17 weeks or 22-24 weeks", "f": "Anomaly scan = 18-22 weeks; NT scan = 11-13 weeks; never confuse the two windows", "r": "Detailed anomaly scan → 18-22 weeks; first-trimester combined screening (NT) → 11-13 weeks", "x": [["A) 11-13 weeks", "11-13 weeks is the nuchal translucency scan window, not the anomaly scan."], ["B) 16-17 weeks", "16-17 weeks is too early — cardiac views are incomplete; the anomaly scan is at 18-22 weeks."], ["D) 22-24 weeks", "22-24 weeks exceeds the optimal window; 18-22 weeks is the standard."]]}, {"n": 21, "s": "A 30-year-old woman at 29 weeks was diagnosed with gestational diabetes at 26 weeks and started on dietary therapy with glucose monitoring. Her fasting glucose is 4.9 mmol/L and her 2-hour postprandial glucose is 6.5 mmol/L. What is the most appropriate management?", "o": [["A", "Start insulin immediately"], ["B", "Continue diet and lifestyle measures with glucose monitoring"], ["C", "Start metformin"], ["D", "Plan induction at 37 weeks"]], "c": ["B)", "Continue diet and lifestyle measures with glucose monitoring"], "co": "Gestational diabetes — stepwise management (diet first)", "ct": "Interpretation", "w": "Dietary modification and glucose monitoring are first-line for gestational diabetes; pharmacological therapy (metformin or insulin) is added only when glucose targets are not achieved.", "d": "Glucose targets being met on diet → continue diet + monitoring; drugs are added only when targets are missed", "t": "Treatment ladder — dietary therapy before drugs in GDM; insulin is reserved for target failure", "f": "GDM ladder: diet → metformin/insulin → delivery planning; never start insulin while diet is working", "r": "GDM achieving targets on diet = continue diet + monitoring; escalate only on persistent target failure", "x": [["A) Start insulin immediately", "Insulin is added only when glycaemic targets are missed despite diet — not while control is adequate."], ["C) Start metformin", "Metformin is started when diet fails; it is not indicated while targets are being met."], ["D) Plan induction at 37 weeks", "Induction is planned on glycaemic control and fetal growth — not for a well-controlled GDM at 29 weeks."]]}, {"n": 22, "s": "A 33-year-old G3P2 has a vaginal delivery and develops postpartum haemorrhage from uterine atony. Oxytocin and ergometrine have been given with uterine massage ongoing, but total blood loss reaches 1400 mL. Which adjunct should be given urgently?", "o": [["A", "Intravenous tranexamic acid 1 g"], ["B", "Oral tranexamic acid 500 mg twice daily"], ["C", "Intravenous vitamin K"], ["D", "Prophylactic fresh frozen plasma"]], "c": ["A)", "Intravenous tranexamic acid 1 g"], "co": "Postpartum haemorrhage — tranexamic acid (time-critical adjunct)", "ct": "Interpretation", "w": "In postpartum haemorrhage, intravenous tranexamic acid 1 g should be given as soon as possible and within 3 hours of onset; it reduces haemorrhage-related maternal mortality.", "d": "Ongoing PPH → IV tranexamic acid 1 g within 3 hours of onset to reduce death from bleeding", "t": "Guideline Version — IV tranexamic acid 1 g within 3 hours of PPH onset is the current standard", "f": "PPH bundle: oxytocin → ergometrine/carboprost → IV TXA 1 g within 3 hours → escalation + surgical measures", "r": "Ongoing PPH → IV tranexamic acid 1 g within 3 hours alongside uterotonics", "x": [["B) Oral tranexamic acid 500 mg twice daily", "Oral tranexamic acid has no role in acute PPH — it must be given IV for rapid effect."], ["C) Intravenous vitamin K", "Vitamin K has no role in acute obstetric haemorrhage (it takes hours and treats deficiency, not atony)."], ["D) Prophylactic fresh frozen plasma", "Prophylactic FFP is not given without coagulopathy or massive transfusion requirements."]]}, {"n": 23, "s": "A 32-year-old G2P1 who had one previous lower-segment caesarean section is now at 39 weeks with a single vertex fetus, estimated fetal weight 3.3 kg, and no other complications. She asks about her options for this delivery. What is the most appropriate counselling?", "o": [["A", "Trial of labour can be offered — discuss the approximately 0.5% risk of uterine rupture"], ["B", "Elective repeat caesarean is the only safe option"], ["C", "External cephalic version should be offered first"], ["D", "Vaginal birth is contraindicated after any caesarean section"]], "c": ["A)", "Trial of labour can be offered — discuss the approximately 0.5% risk of uterine rupture"], "co": "Previous caesarean — VBAC (trial of labour) counselling", "ct": "Analysis/synthesis (counselling + risk-benefit)", "w": "After one lower-segment caesarean with no contraindications (vertex, term, normal fetal size), trial of labour after caesarean (VBAC) is a reasonable option and should be offered with counselling about the small (approximately 0.5%) risk of uterine rupture.", "d": "One lower-segment CS + vertex term fetus + no contraindications → TOLAC is a safe option with a small uterine rupture risk", "t": "Partial Truth — 'previous caesarean equals repeat caesarean' ignores that most women are TOLAC candidates", "f": "VBAC candidates: 1 lower-segment CS, vertex, EFW <4 kg; avoid TOLAC after a classical scar, >2 CS, or prior rupture", "r": "One lower-segment CS without contraindications → offer TOLAC with rupture-risk counselling (~0.5%)", "x": [["B) Elective repeat caesarean is the only safe option", "Elective repeat caesarean is an option but not mandatory — most women with one lower-segment scar are TOLAC candidates."], ["C) External cephalic version should be offered first", "ECV is for breech or transverse lie, not a vertex fetus."], ["D) Vaginal birth is contraindicated after any caesarean section", "Vaginal birth is not contraindicated after a lower-segment caesarean; TOLAC is widely offered."]]}, {"n": 24, "s": "A 32-year-old G2P1 at 33 weeks presents with sudden severe constant abdominal pain and dark red vaginal bleeding. The uterus is firm and tender. Fetal heart sounds are absent and ultrasound confirms intrauterine fetal demise. Her blood pressure is 115/75 mmHg and the clotting screen is normal. What is the most appropriate management?", "o": [["A", "Vaginal delivery with close monitoring of coagulation status"], ["B", "Emergency caesarean section"], ["C", "Expectant management with delivery at 34 weeks"], ["D", "Total abdominal hysterectomy"]], "c": ["A)", "Vaginal delivery with close monitoring of coagulation status"], "co": "Placental abruption with intrauterine fetal demise — mode of delivery", "ct": "Analysis/synthesis", "w": "In placental abruption with intrauterine fetal demise and a haemodynamically stable mother, vaginal delivery is preferred. Caesarean section is reserved for maternal indications (e.g., uncontrolled haemorrhage or coagulopathy) because the fetus is already dead.", "d": "Abruption + fetal demise + stable mother + normal clotting → vaginal delivery; a dead fetus is never an indication for caesarean section", "t": "Treatment misdirection — caesarean for a non-viable fetus when vaginal delivery is the preferred route", "f": "Fetal demise from abruption = vaginal delivery unless the mother is unstable; watch for DIC with concealed haemorrhage", "r": "Abruption + fetal demise + stable mother = vaginal delivery with serial clotting monitoring (DIC watch)", "x": [["B) Emergency caesarean section", "Emergency caesarean is not indicated for fetal demise alone — the dead fetus can and should be delivered vaginally unless the mother is unstable."], ["C) Expectant management with delivery at 34 weeks", "Leaving a bleeding abruption in situ permits ongoing concealed haemorrhage and DIC — delivery is the treatment."], ["D) Total abdominal hysterectomy", "Hysterectomy is reserved for uncontrollable haemorrhage, not as primary management here."]]}, {"n": 25, "s": "A 31-year-old G2P1 at 33 weeks has a fundal height 4 cm below dates on two consecutive visits, with normal blood pressure. Ultrasound shows an estimated fetal weight below the 3rd centile, oligohydramnios, and absent end-diastolic flow in the umbilical artery Doppler. What is the most appropriate management?", "o": [["A", "Give antenatal corticosteroids and plan delivery"], ["B", "Repeat CTG in 2 weeks and recheck growth"], ["C", "Reassure the mother — constitutionally small baby"], ["D", "Start oral labetalol"]], "c": ["A)", "Give antenatal corticosteroids and plan delivery"], "co": "Fetal growth restriction — absent end-diastolic flow and delivery planning", "ct": "Analysis/synthesis (Doppler staging → delivery decision)", "w": "Severe fetal growth restriction with absent end-diastolic flow in the umbilical artery at 33 weeks indicates significant placental insufficiency — antenatal corticosteroids followed by planned delivery is indicated.", "d": "FGR + oligohydramnios + absent end-diastolic flow at 33 weeks → steroids + planned delivery; not watchful waiting", "t": "Priority inversion — absent end-diastolic flow demands steroids + planned delivery, not a repeat CTG in 2 weeks", "f": "Doppler: raised PI → monitor; absent EDF → steroids + deliver by ~34 weeks; reversed EDF → deliver immediately", "r": "FGR + absent end-diastolic flow at 33 weeks → betamethasone + planned delivery after the steroid course", "x": [["B) Repeat CTG in 2 weeks and recheck growth", "Delayed reassessment permits further deterioration of an already compromised fetus — action is required."], ["C) Reassure the mother — constitutionally small baby", "The triad of <3rd centile, oligohydramnios, and absent diastolic flow is pathological, not constitutional."], ["D) Start oral labetalol", "Labetalol is for hypertension — this woman is normotensive."]]}, {"n": 26, "s": "A 31-year-old woman, G2P1, at 20 weeks of gestation with a known 8 cm anterior intramural fibroid presents with acute, sharply localized pain over the mass and a low-grade fever of 37.9°C for 6 hours. The uterus away from the mass is soft, there is no vaginal bleeding, and the fetal heart is normal. What is the most likely diagnosis and management?", "o": [["A", "Red degeneration of the fibroid — analgesia, hydration and observation"], ["B", "Placental abruption — immediate caesarean delivery"], ["C", "Torsion of a pedunculated fibroid — urgent myomectomy"], ["D", "Sarcomatous change — total hysterectomy"]], "c": ["A)", "Red degeneration of the fibroid — analgesia, hydration and observation"], "co": "Uterine fibroids — red (carneous) degeneration in pregnancy", "ct": "Interpretation (pain pattern localizes to the fibroid)", "w": "Acute pain over a known fibroid with low-grade fever, a soft non-tender uterus elsewhere, and a normal fetal heart is classic red (carneous) degeneration, the most common complication of fibroids in pregnancy; it is managed conservatively with analgesia, hydration and observation.", "d": "Acute pain localized to a KNOWN fibroid + low-grade fever + soft uterus + normal fetal heart in pregnancy = red degeneration → conservative", "t": "Clinical Mimic — fibroid degeneration mistaken for placental abruption", "f": "Pain over a fibroid + fever + soft uterus = red degeneration (analgesia); tense tender uterus + fetal distress = abruption", "r": "Pregnancy + pain over known fibroid + low-grade fever = red degeneration → conservative care", "x": [["B) Placental abruption — immediate caesarean delivery", "Placental abruption produces a tense, woody, tender uterus with fetal compromise and often vaginal bleeding — not pain localized to one mass with a soft uterus and normal fetal heart."], ["C) Torsion of a pedunculated fibroid — urgent myomectomy", "Torsion of a pedunculated fibroid gives abrupt severe pain with peritonism and requires a pedunculated lesion; this is an intramural fibroid."], ["D) Sarcomatous change — total hysterectomy", "Sarcomatous change does not present acutely in pregnancy with localized pain and fever; it is a chronic, enlarging process."]]}, {"n": 27, "s": "A 58-year-old woman, 6 years postmenopausal, has an incidental finding on ultrasound of a 3.5 cm thin-walled, unilocular, anechoic cyst in the right ovary. There are no septations, solid areas or mural nodules, and CA-125 is normal. She is asymptomatic. What is the most appropriate management?", "o": [["A", "Repeat ultrasound surveillance"], ["B", "Laparoscopic bilateral salpingo-oophorectomy"], ["C", "Exploratory laparotomy"], ["D", "Neoadjuvant chemotherapy"]], "c": ["A)", "Repeat ultrasound surveillance"], "co": "Benign ovarian cysts — simple cyst in the postmenopausal woman", "ct": "Analysis/synthesis (simple cyst features override menopausal alarm)", "w": "A 3.5 cm simple (unilocular, anechoic, thin-walled) cyst with normal morphology and normal CA-125 is almost always benign even after menopause; ultrasound surveillance rather than surgery is appropriate, with intervention reserved for growth, complexity or symptoms.", "d": "Small unilocular anechoic cyst + no solid elements + normal CA-125 = simple cyst → surveillance, not surgery", "t": "Overthinking — a simple postmenopausal cyst is not a cancer hunt", "f": "Simple cyst + normal CA-125 = surveillance regardless of menopausal status; complex/mural nodule/growth = surgery", "r": "Simple postmenopausal cyst <5 cm with normal CA-125 = conservative ultrasound surveillance", "x": [["B) Laparoscopic bilateral salpingo-oophorectomy", "Bilateral salpingo-oophorectomy is disproportionate for a 3.5 cm simple cyst with normal CA-125 and no complex features."], ["C) Exploratory laparotomy", "Exploratory laparotomy is reserved for suspected malignancy or complications, which are absent here."], ["D) Neoadjuvant chemotherapy", "Chemotherapy treats malignant disease; there is no evidence of malignancy in a simple cyst with normal CA-125."]]}, {"n": 28, "s": "A 33-year-old woman presents with heavy menstrual bleeding and intermenstrual spotting for 5 months. Transvaginal ultrasound shows a 1.8 cm echogenic lesion within the uterine cavity whose exact origin cannot be determined. Which investigation best distinguishes a polyp from a submucous fibroid?", "o": [["A", "Saline infusion sonohysterography"], ["B", "Outpatient blind endometrial biopsy"], ["C", "MRI of the pelvis"], ["D", "Hysterosalpingography"]], "c": ["A)", "Saline infusion sonohysterography"], "co": "Abnormal uterine bleeding (PALM-COEIN) — polyp vs submucous fibroid localisation", "ct": "Interpretation (intracavitary lesion needs localisation)", "w": "Saline infusion sonohysterography (SIS) distends the cavity and precisely defines the site, size and origin of an intracavitary lesion, distinguishing a polyp (AUB-P) from a submucous fibroid (AUB-L) and guiding hysteroscopic resection.", "d": "Intracavitary echogenic lesion of uncertain origin → saline infusion sonohysterography separates AUB-P (polyp) from AUB-L (submucous fibroid)", "t": "Investigation hierarchy — SIS localises what blind biopsy cannot see", "f": "Intracavitary lesion on TVS → SIS before any resection; blind biopsy can miss a focal polyp", "r": "Intracavitary lesion of uncertain origin = saline infusion sonohysterography", "x": [["B) Outpatient blind endometrial biopsy", "A blind endometrial biopsy targets the endometrium diffusely and can miss a focal polyp or submucous fibroid; it does not map the cavity."], ["C) MRI of the pelvis", "MRI characterises myometrial and deep pelvic disease but is not the first-line tool for a small intracavitary lesion already seen on ultrasound."], ["D) Hysterosalpingography", "Hysterosalpingography tests tubal patency and is not the investigation for intracavitary lesion characterisation."]]}, {"n": 29, "s": "A 26-year-old woman underwent suction evacuation of a complete hydatidiform mole 10 weeks ago. Her β-hCG fell from 180,000 to 400 IU/L, but four consecutive weekly values have been 400–420 IU/L. She has no vaginal bleeding and the uterus is normal on examination. What is the most appropriate next step?", "o": [["A", "Continue weekly β-hCG surveillance"], ["B", "Repeat uterine evacuation"], ["C", "Proceed to gestational trophoblastic neoplasia staging and chemotherapy"], ["D", "Total hysterectomy"]], "c": ["C)", "Proceed to gestational trophoblastic neoplasia staging and chemotherapy"], "co": "Post-molar gestational trophoblastic neoplasia — diagnosis (hCG plateau)", "ct": "Interpretation (hCG plateau pattern after molar evacuation)", "w": "After molar evacuation, a β-hCG plateau across four values over at least 3 weeks defines persistent gestational trophoblastic neoplasia; even without symptoms this warrants GTN staging and chemotherapy (single-agent methotrexate when low risk), not continued waiting.", "d": "hCG plateau over 4 values across 3 weeks after molar evacuation = persistent GTN → staging + chemotherapy", "t": "Negative discrimination — a hCG plateau is disease, not a benign delay", "f": "Plateau ×4 over 3 weeks or rise ×2 over 2 weeks = GTN → refer for chemotherapy", "r": "Post-molar hCG plateau over 3 weeks (or rise over 2 weeks) = persistent GTN → staging + chemotherapy", "x": [["A) Continue weekly β-hCG surveillance", "A 3-week plateau is not a benign lag — the surveillance definition of persistent disease has been met and continued observation delays treatment."], ["B) Repeat uterine evacuation", "Repeat evacuation is only for retained products with falling or stable hCG and a uterine mass; it is not the treatment for a biochemical plateau."], ["D) Total hysterectomy", "Hysterectomy does not treat the metastatic potential of GTN and is not first-line for post-molar persistent disease in a young woman."]]}, {"n": 30, "s": "A 64-year-old woman has had intense vulvar itching and burning for 2 years. Examination shows white, atrophic, parchment-like plaques with fissuring affecting the labia and perianal skin. Which is the most appropriate first-line treatment?", "o": [["A", "Ultrapotent topical corticosteroid (clobetasol)"], ["B", "Topical estrogen cream"], ["C", "Oral fluconazole"], ["D", "Vaginal clotrimazole"]], "c": ["A)", "Ultrapotent topical corticosteroid (clobetasol)"], "co": "Lichen sclerosus — diagnosis and first-line ultrapotent steroid", "ct": "Analysis/synthesis (atrophic white vulvar plaques across differentials)", "w": "White atrophic plaques with fissuring on the labia and perianal skin are diagnostic of lichen sclerosus, whose first-line treatment is an ultrapotent topical corticosteroid such as clobetasol; topical estrogen is for atrophic vaginitis, not this plaque pattern.", "d": "White parchment-like plaques + fissuring in an older woman = lichen sclerosus → ultrapotent topical steroid", "t": "Treatment misdirection — estrogen cream for a steroid-responsive condition", "f": "White atrophic vulvar plaques = lichen sclerosus = clobetasol; estrogen is for vaginal atrophy alone", "r": "Lichen sclerosus (white atrophic plaques) = ultrapotent topical corticosteroid first-line", "x": [["B) Topical estrogen cream", "Topical estrogen treats atrophic vaginitis and genitourinary symptoms of menopause; it cannot treat the inflammatory plaques of lichen sclerosus."], ["C) Oral fluconazole", "Oral fluconazole is for candida vulvovaginitis, which produces itching with a discharge and erythema, not atrophic white plaques."], ["D) Vaginal clotrimazole", "Vaginal clotrimazole treats superficial candidiasis; the appearance and 2-year course here are not fungal."]]}, {"n": 31, "s": "A 31-year-old woman with stage II endometriosis diagnosed at laparoscopy has been trying to conceive for 2 years. Her partner's semen analysis is normal and tubal patency is confirmed. A colleague suggested GnRH agonist therapy. Which management is most appropriate to improve her chance of conception?", "o": [["A", "Laparoscopic excision of endometriotic lesions"], ["B", "GnRH agonist suppression for 6 months before attempting conception"], ["C", "Danazol for 6 months"], ["D", "Combined oral contraceptive for 6 months"]], "c": ["A)", "Laparoscopic excision of endometriotic lesions"], "co": "Endometriosis — surgery improves fertility; medical suppression does not", "ct": "Interpretation (fertility goal reorders treatment choice)", "w": "Laparoscopic ablation or excision of endometriosis improves spontaneous pregnancy rates in endometriosis-associated infertility, whereas GnRH agonist or other ovarian suppression does not improve fertility and only postpones attempts at conception.", "d": "Endometriosis-associated infertility → laparoscopic excision raises spontaneous conception; ovarian suppression only delays conception", "t": "Opposite — ovarian suppression chosen when conception is the goal", "f": "Endometriosis + infertility = surgery for fertility; GnRH/progestins are for pain control only", "r": "Endometriosis-associated subfertility = laparoscopic excision/ablation (medical suppression does not help conception)", "x": [["B) GnRH agonist suppression for 6 months before attempting conception", "GnRH agonist creates a temporary menopause that suppresses ovulation for 6 months without any fertility benefit — time is lost, not gained."], ["C) Danazol for 6 months", "Danazol is an androgenic suppressive agent for pain; it is not used for fertility and has significant side effects."], ["D) Combined oral contraceptive for 6 months", "The COC suppresses symptoms but does not improve spontaneous conception rates and cannot be used while conceiving."]]}, {"n": 32, "s": "A 21-year-old competitive long-distance runner (BMI 17.5 kg/m²) has had amenorrhea for 7 months and a recent metatarsal stress fracture. A pregnancy test is negative. FSH is 3.1 IU/L, LH 2.4 IU/L, estradiol 18 pg/mL, and prolactin is normal. Which diagnosis is most likely?", "o": [["A", "Functional hypothalamic amenorrhea"], ["B", "Polycystic ovary syndrome"], ["C", "Premature ovarian insufficiency"], ["D", "Prolactinoma"]], "c": ["A)", "Functional hypothalamic amenorrhea"], "co": "Secondary amenorrhea — functional hypothalamic amenorrhea in energy deficit", "ct": "Analysis/synthesis (low FSH + energy deficit vs hyperandrogenic mimics)", "w": "Severe energy deficit in an endurance athlete suppresses GnRH drive, producing low FSH and LH, hypoestrogenemia and amenorrhea with bone loss (stress fracture) — functional hypothalamic amenorrhea, managed by reversing energy deficit and replacing estrogen for bone health.", "d": "Low BMI + heavy training + LOW FSH/LH + stress fracture = functional hypothalamic amenorrhea (energy deficit suppresses GnRH)", "t": "Partial Truth — PCOS fragments misread in an energy-deficient athlete", "f": "Low FSH + thin athlete + amenorrhea = hypothalamic (energy deficit); high FSH = ovarian failure; prolactinoma has high prolactin", "r": "Amenorrhea + low FSH/LH + low BMI in an athlete = functional hypothalamic amenorrhea", "x": [["B) Polycystic ovary syndrome", "PCOS presents with hyperandrogenism (hirsutism, acne) and normal-to-high LH/FSH ratio, not low gonadotropins in a thin athlete."], ["C) Premature ovarian insufficiency", "Premature ovarian insufficiency would show a HIGH FSH (menopausal range), not a low FSH of 3.1 IU/L."], ["D) Prolactinoma", "A prolactinoma would show elevated prolactin with possible galactorrhea; her prolactin is normal."]]}, {"n": 33, "s": "A 32-year-old woman has a profuse, frothy, yellow-green, malodorous vaginal discharge with vulvar irritation for 1 week. Speculum examination shows punctate hemorrhagic spots on the cervix (strawberry cervix). A wet mount shows motile flagellated organisms. Which organism is the cause?", "o": [["A", "Trichomonas vaginalis"], ["B", "Gardnerella vaginalis"], ["C", "Candida albicans"], ["D", "Neisseria gonorrhoeae"]], "c": ["A)", "Trichomonas vaginalis"], "co": "Vulvovaginal infections — Trichomonas vaginalis identification", "ct": "Recall (wet-mount morphology identifies the organism)", "w": "A frothy, malodorous, yellow-green discharge with punctate cervical hemorrhages (strawberry cervix) and motile flagellated organisms on wet mount is classic Trichomonas vaginalis, a protozoan treated with metronidazole (with partner treatment).", "d": "Frothy yellow-green discharge + strawberry cervix + motile flagellates = Trichomonas vaginalis", "t": "Organism homogeneity — all four cause vaginal discharge", "f": "Frothy + flagellates = Trichomonas (metronidazole); fishy + clue cells = Gardnerella; curdy + pseudohyphae = Candida", "r": "Motile flagellates + frothy discharge + strawberry cervix = Trichomonas vaginalis", "x": [["B) Gardnerella vaginalis", "Gardnerella vaginalis causes bacterial vaginosis — a thin gray fishy discharge with clue cells, not flagellated organisms."], ["C) Candida albicans", "Candida albicans produces a thick white curdy discharge with yeast forms and pseudohyphae on microscopy."], ["D) Neisseria gonorrhoeae", "Neisseria gonorrhoeae causes purulent endocervical discharge with gram-negative intracellular diplococci, not motile flagellates."]]}, {"n": 34, "s": "A 48-year-old woman, BMI 34 kg/m², reports leaking urine when she coughs, sneezes or laughs for 6 months. She has no urgency or nocturia, voids normally, and the urine dipstick is negative. Which is the most appropriate first-line treatment?", "o": [["A", "Supervised pelvic floor muscle training"], ["B", "Oxybutynin"], ["C", "Immediate mid-urethral sling"], ["D", "Vaginal estrogen cream"]], "c": ["A)", "Supervised pelvic floor muscle training"], "co": "Urinary incontinence — stress incontinence and first-line conservative therapy", "ct": "Interpretation (leak pattern with cough = stress incontinence)", "w": "Leakage triggered only by cough, sneeze or laugh without urgency defines stress urinary incontinence; supervised pelvic floor muscle training of at least 3 months is the first-line treatment before any surgical or anticholinergic step.", "d": "Leak only on cough/sneeze/laugh with no urgency = stress incontinence → PFMT first-line", "t": "Synonym Swap — stress incontinence treated with urge-continence drugs", "f": "Leak with cough = stress (PFMT); leak with urgency = overactive bladder (anticholinergics)", "r": "Stress urinary incontinence = pelvic floor muscle training first-line (surgery only if conservative fails)", "x": [["B) Oxybutynin", "Oxybutynin and other anticholinergics treat urgency (overactive bladder), not stress leakage on coughing."], ["C) Immediate mid-urethral sling", "A mid-urethral sling is offered only after a trial of conservative therapy; it is not first-line."], ["D) Vaginal estrogen cream", "Vaginal estrogen addresses genitourinary syndrome of menopause; it is not first-line treatment for stress incontinence."]]}, {"n": 35, "s": "A 29-year-old woman who had evacuation of a hydatidiform mole 6 months ago has a rising β-hCG, now 150,000 IU/L. Chest X-ray shows multiple bilateral lung nodules; CT shows no liver or brain metastases. Transvaginal ultrasound shows a 4 cm myometrial lesion. Her WHO/FIGO prognostic score is 9. Which regimen is most appropriate?", "o": [["A", "Single-agent methotrexate"], ["B", "EMA-CO (etoposide, methotrexate, actinomycin-D, cyclophosphamide, vincristine)"], ["C", "Actinomycin-D alone"], ["D", "Hysterectomy alone"]], "c": ["B)", "EMA-CO (etoposide, methotrexate, actinomycin-D, cyclophosphamide, vincristine)"], "co": "Gestational trophoblastic neoplasia — FIGO stage III, high-risk score → EMA-CO", "ct": "Recall (WHO score ≥7 pairs with the EMA-CO regimen)", "w": "A prognostic score of 9 places this woman in high-risk gestational trophoblastic neoplasia (≥7), which is treated with combination chemotherapy — EMA-CO; single-agent methotrexate is for low-risk disease (score ≤6).", "d": "WHO/FIGO score 9 (≥7) = high-risk GTN → EMA-CO, not single-agent methotrexate", "t": "Unit/Number — WHO score arithmetic flips the regimen", "f": "Score ≤6 = single-agent methotrexate; score ≥7 = EMA-CO; don't stop at 'lung mets = stage III'", "r": "GTN with WHO score ≥7 (high risk) = EMA-CO combination chemotherapy", "x": [["A) Single-agent methotrexate", "Single-agent methotrexate is the low-risk (score ≤6) regimen; a score of 9 demands combination therapy."], ["C) Actinomycin-D alone", "Actinomycin-D alone is another single-agent option for low-risk disease and is inadequate for high-risk GTN."], ["D) Hysterectomy alone", "Hysterectomy does not treat the metastatic lung disease and is not the primary therapy for high-risk GTN in a young woman."]]}, {"n": 36, "s": "A 44-year-old woman, BMI 36 kg/m², has irregular heavy vaginal bleeding for 7 months. Endometrial biopsy shows complex hyperplasia with cytological atypia. She has completed her family. What is the most appropriate management?", "o": [["A", "Total hysterectomy"], ["B", "Endometrial ablation"], ["C", "Levonorgestrel intrauterine system with surveillance"], ["D", "GnRH agonist for 6 months"]], "c": ["A)", "Total hysterectomy"], "co": "Premalignant disease of the uterus — complex atypical hyperplasia management", "ct": "Analysis/synthesis (premalignant biopsy dictates definitive surgery)", "w": "Complex hyperplasia with atypia carries a substantial risk of progression to (or coexisting) endometrial carcinoma; with her family completed, total hysterectomy is the definitive management, whereas progestin therapy is reserved for women who wish to preserve fertility.", "d": "Complex atypical hyperplasia + family completed = hysterectomy (up to ~30% progression risk); hormonal options are fertility-sparing only", "t": "What NOT to do — ablation in a premalignant cavity", "f": "Atypical endometrial hyperplasia + family complete = hysterectomy; progestins only when fertility is desired", "r": "Complex atypical hyperplasia with completed family = total hysterectomy", "x": [["B) Endometrial ablation", "Endometrial ablation destroys the surface but cannot guarantee removal of atypical disease and obscures later surveillance — it is never used for premalignancy."], ["C) Levonorgestrel intrauterine system with surveillance", "The LNG-IUS with surveillance is a fertility-sparing option; it is not the definitive choice when the family is complete."], ["D) GnRH agonist for 6 months", "GnRH agonist only temporarily suppresses the endometrium and is not a treatment for atypical hyperplasia."]]}, {"n": 37, "s": "A 34-year-old woman attends routine cervical screening. Primary HPV testing is positive for a high-risk genotype other than 16 or 18, and cytology is negative (NILM). She is asymptomatic. What is the most appropriate next step?", "o": [["A", "Immediate colposcopy"], ["B", "Repeat HPV and cytology testing in 12 months"], ["C", "Therapeutic LLETZ excision"], ["D", "HPV vaccination series now"]], "c": ["B)", "Repeat HPV and cytology testing in 12 months"], "co": "Cervical cancer screening — HPV-primary triage of non-16/18 genotypes", "ct": "Interpretation (HPV genotype triage in the screening algorithm)", "w": "In HPV-primary screening, a positive non-16/18 high-risk genotype with negative cytology carries low short-term risk and is managed by repeat co-testing in 12 months; immediate colposcopy is reserved for HPV 16/18 or any abnormal cytology.", "d": "Non-16/18 hrHPV + negative cytology = 12-month surveillance; only HPV 16/18 or abnormal cytology go straight to colposcopy", "t": "Guideline Version — HPV-primary triage replaced the reflex-colposcopy era", "f": "Non-16/18 + NILM = retest at 12 months; 16/18 or ASC-US+ = colposcopy", "r": "hrHPV positive (non-16/18) + normal cytology = repeat co-testing in 12 months", "x": [["A) Immediate colposcopy", "Immediate colposcopy is the pathway for HPV 16/18 or abnormal cytology, not for other high-risk genotypes with negative cytology."], ["C) Therapeutic LLETZ excision", "LLETZ treats histologically confirmed CIN; it is never a response to a screening test result alone."], ["D) HPV vaccination series now", "Vaccination protects against future acquisition of HPV types; it does not triage a current positive test."]]}, {"n": 38, "s": "A 36-year-old woman presents with 5 months of amenorrhea after years of regular cycles. She reports hot flushes, night sweats and vaginal dryness. FSH is 48 and 51 IU/L on two occasions with a low estradiol; karyotype is normal. What is the most appropriate management?", "o": [["A", "Estrogen–progestogen HRT until around age 51"], ["B", "Clomiphene citrate for ovulation induction"], ["C", "Reassurance with calcium and vitamin D alone"], ["D", "Progestogen-only contraception"]], "c": ["A)", "Estrogen–progestogen HRT until around age 51"], "co": "Premature ovarian insufficiency — diagnosis and HRT indication", "ct": "Interpretation (high FSH + amenorrhea at 36 = POI)", "w": "Amenorrhea with FSH above 40 before age 40 defines premature ovarian insufficiency; estrogen–progestogen HRT until around the natural menopause age is indicated — not just reassurance — to control vasomotor symptoms and protect bone and cardiovascular health.", "d": "Amenorrhea + FSH >40 before age 40 = premature ovarian insufficiency → HRT until average menopause age", "t": "Age-appropriate differential — menopause at 36 is disease, not a stage of life", "f": "Amenorrhea + FSH >40 under age 40 = POI → HRT until ~51; ovulatory agents are futile (ovarian failure)", "r": "POI (FSH >40 before 40) = combined HRT until age ~51", "x": [["B) Clomiphene citrate for ovulation induction", "Clomiphene induces ovulation only when the ovary can respond; in POI the ovaries are failing and no ovulatory agent will work."], ["C) Reassurance with calcium and vitamin D alone", "Calcium and vitamin D are adjuncts for bone health but cannot replace the estrogen deficit that drives symptoms and bone loss."], ["D) Progestogen-only contraception", "Progestogen-only contraception neither corrects hypoestrogenism nor controls vasomotor symptoms."]]}, {"n": 39, "s": "A 48-year-old woman presents with postcoital bleeding for 3 months. Speculum examination shows a 4 cm friable cervical mass; biopsy confirms squamous cell carcinoma. Examination under anesthesia shows bilateral parametrial involvement without fixation to the pelvic side wall. Which treatment is most appropriate?", "o": [["A", "Radical hysterectomy with lymphadenectomy"], ["B", "Chemoradiotherapy (external beam, brachytherapy and weekly cisplatin)"], ["C", "Simple total hysterectomy"], ["D", "Observation with restaging in 3 months"]], "c": ["B)", "Chemoradiotherapy (external beam, brachytherapy and weekly cisplatin)"], "co": "Cervical cancer — stage IIB is treated with chemoradiotherapy, not surgery", "ct": "Recall (FIGO stage IIB pairs with chemoradiation)", "w": "Parametrial extension without pelvic side-wall fixation defines FIGO stage IIB cervical cancer, which is treated with definitive chemoradiotherapy (external beam, brachytherapy and weekly cisplatin); radical hysterectomy is reserved for early stages (≤IIA).", "d": "Parametrial involvement = stage IIB → chemoradiotherapy; surgery is reserved for stage ≤IIA", "t": "Treatment misdirection — radical surgery offered for a nonsurgical stage", "f": "Parametrial spread = IIB = chemoradiation, never up-front hysterectomy", "r": "Stage IIB cervical cancer (parametrial involvement) = chemoradiotherapy", "x": [["A) Radical hysterectomy with lymphadenectomy", "Radical hysterectomy is an option for early-stage disease (≤IIA); parametrial involvement makes surgery the wrong primary modality."], ["C) Simple total hysterectomy", "Simple hysterectomy does not address parametrial invasion and is not a treatment for stage IIB disease."], ["D) Observation with restaging in 3 months", "Stage IIB is already defined and highly curable with chemoradiation — delaying treatment is inappropriate."]]}, {"n": 40, "s": "A 57-year-old woman with breast cancer has taken tamoxifen for 3 years. She reports 2 weeks of postmenopausal vaginal bleeding. Transvaginal ultrasound shows an endometrial thickness of 9 mm. What is the most appropriate next step?", "o": [["A", "Outpatient endometrial biopsy"], ["B", "Repeat ultrasound in 6 months"], ["C", "CT of the abdomen and pelvis"], ["D", "Stop tamoxifen and observe"]], "c": ["A)", "Outpatient endometrial biopsy"], "co": "Endometrial cancer risk — postmenopausal bleeding on tamoxifen requires tissue diagnosis", "ct": "Analysis/synthesis (tamoxifen exposure + bleeding → tissue diagnosis)", "w": "Postmenopausal bleeding on tamoxifen — which acts as an estrogen agonist on the endometrium — requires outpatient endometrial biopsy for tissue diagnosis; ultrasound thickness alone cannot exclude polyps, hyperplasia or carcinoma.", "d": "Tamoxifen is an endometrial agonist → any postmenopausal bleeding mandates histology, not imaging follow-up", "t": "Iatrogenic trap — tamoxifen agonist effect on the endometrium", "f": "Tamoxifen + any postmenopausal bleeding = endometrial biopsy, always", "r": "Postmenopausal bleeding on tamoxifen = outpatient endometrial biopsy (histology decides)", "x": [["B) Repeat ultrasound in 6 months", "Surveillance imaging delays diagnosis; an endometrial thickness of 9 mm with bleeding requires tissue, not another scan in 6 months."], ["C) CT of the abdomen and pelvis", "CT stages known malignancy; it cannot diagnose or exclude endometrial pathology in this setting."], ["D) Stop tamoxifen and observe", "Stopping tamoxifen is an oncology decision and does not establish the cause of the bleeding."]]}, {"n": 41, "s": "A 55-year-old woman, para 4, reports a dragging sensation and something coming down for the past year, worse at the end of the day. On examination with Valsalva the cervix comes down to the introitus (stage III prolapse). She has COPD and obesity, is not sexually active, and wishes to avoid surgery. What is the most appropriate management?", "o": [["A", "Vaginal ring pessary"], ["B", "Vaginal hysterectomy with repair"], ["C", "Pelvic floor muscle training alone"], ["D", "Manchester repair"]], "c": ["A)", "Vaginal ring pessary"], "co": "Utero-vaginal prolapse — pessary as first-line conservative management", "ct": "Interpretation (symptomatic stage III prolapse with surgical risk)", "w": "A woman with symptomatic stage III prolapse who is unfit for or declines surgery is managed with a vaginal pessary, which relieves the bulge and dragging symptoms; pelvic floor muscle training alone cannot support stage III prolapse.", "d": "Symptomatic prolapse + poor surgical candidate + wants to avoid surgery = ring pessary, not surgery or PFMT alone", "t": "Treatment ladder — pessary before surgery in symptomatic prolapse", "f": "Symptomatic prolapse + surgical risk or preference = pessary first; surgery when pessary fails or declined", "r": "Symptomatic prolapse unfit for/declining surgery = vaginal pessary (PFMT alone insufficient for stage III)", "x": [["B) Vaginal hysterectomy with repair", "Vaginal hysterectomy with repair is effective but the patient explicitly wishes to avoid surgery and has significant operative risk."], ["C) Pelvic floor muscle training alone", "Pelvic floor muscle training helps mild prolapse; it cannot correct a stage III descent at the introitus."], ["D) Manchester repair", "Manchester repair is a surgical procedure for uterovaginal prolapse and is not appropriate when the patient declines surgery."]]}, {"n": 42, "s": "A 24-year-old nulliparous woman presents with sudden severe left iliac fossa pain and vomiting over 4 hours. She is afebrile. A tender 7 cm left adnexal mass is palpable. Transvaginal ultrasound shows an enlarged left ovary with absent arterial and venous flow on Doppler. What is the most appropriate immediate management?", "o": [["A", "Urgent laparoscopy with detorsion and ovarian conservation"], ["B", "Intravenous antibiotics for pelvic inflammatory disease"], ["C", "Methotrexate for suspected ectopic pregnancy"], ["D", "Analgesia and outpatient ultrasound review in 2 weeks"]], "c": ["A)", "Urgent laparoscopy with detorsion and ovarian conservation"], "co": "Ovarian torsion — surgical emergency with ovarian conservation", "ct": "Analysis/synthesis (Doppler-confirmed diagnosis forces the surgical decision)", "w": "Acute severe pain with an adnexal mass and absent arterial and venous flow on Doppler confirms ovarian torsion, a surgical emergency; immediate laparoscopy with detorsion — conserving the ovary even if congested — is the standard of care in a young woman.", "d": "Sudden pelvic pain + adnexal mass + absent Doppler flow = torsion → urgent laparoscopy with detorsion", "t": "Priority inversion — operating-room decision delayed while antibiotics are chased", "f": "Adnexal mass + absent flow + acute pain = torsion = same-day laparoscopy, not antibiotics or observation", "r": "Acute pelvic pain + adnexal mass + absent Doppler flow = torsion → urgent laparoscopic detorsion", "x": [["B) Intravenous antibiotics for pelvic inflammatory disease", "PID causes fever, cervical motion tenderness and bilateral pain — and would not show absent Doppler ovarian flow."], ["C) Methotrexate for suspected ectopic pregnancy", "Methotrexate treats ectopic pregnancy, which would show a positive pregnancy test and adnexal ring, not an ischemic ovary."], ["D) Analgesia and outpatient ultrasound review in 2 weeks", "Observation risks ovarian necrosis and loss of the ovary — torsion with absent flow is a same-day surgical emergency."]]}, {"n": 43, "s": "A 38-year-old woman, G0, with regular 28-day cycles has been trying to conceive for 7 months. Her 41-year-old partner has no children and no known health problems. Neither partner has had a previous pregnancy. What is the most appropriate next step?", "o": [["A", "Reassure and reassess at 12 months of trying"], ["B", "Refer for fertility evaluation now"], ["C", "Start clomiphene citrate empirically"], ["D", "Order genetic karyotyping of both partners first"]], "c": ["B)", "Refer for fertility evaluation now"], "co": "Subfertility — age-adjusted timing of referral (≥35 years)", "ct": "Recall/interpretation (age-adjusted 6-month referral rule)", "w": "In a woman aged 35 or older, fertility evaluation is offered after 6 months of unsuccessful attempts rather than 12; at 38 years with 7 months of trying, referral for evaluation — not continued waiting — is the appropriate next step.", "d": "Age ≥35 shortens the 12-month wait — evaluation now, not at 12 months", "t": "Guideline Version — the 12-month clock shortens at age 35", "f": "Age ≥35 = evaluate at 6 months; age <35 = evaluate at 12 months", "r": "Woman ≥35 with 6 months of unsuccessful attempts = refer for fertility evaluation", "x": [["A) Reassure and reassess at 12 months of trying", "The 12-month threshold applies to women under 35; ovarian reserve declines faster after 35, so evaluation is expedited."], ["C) Start clomiphene citrate empirically", "Clomiphene is not started empirically without an evaluation confirming anovulation; her cycles are regular."], ["D) Order genetic karyotyping of both partners first", "Karyotyping is not a first-line test; it is reserved for specific indications such as recurrent loss or suspected chromosomal disorders."]]}, {"n": 44, "s": "A 32-year-old woman with a copper intrauterine device was diagnosed with pelvic inflammatory disease and treated with outpatient oral doxycycline and ceftriaxone. After 3 days she remains febrile at 38.6°C with worsening right iliac fossa pain. Transvaginal ultrasound shows a 6.5 cm complex right adnexal mass with septations. What is the most appropriate management?", "o": [["A", "Continue the oral antibiotic course at home"], ["B", "Admission for intravenous antibiotics and image-guided or surgical drainage"], ["C", "Add oral fluconazole to the current regimen"], ["D", "Remove the intrauterine device and continue oral therapy at home"]], "c": ["B)", "Admission for intravenous antibiotics and image-guided or surgical drainage"], "co": "Tubo-ovarian abscess — complication of PID requiring admission and drainage", "ct": "Interpretation (failure of outpatient PID therapy signals an abscess)", "w": "Persistent fever despite 72 hours of outpatient antibiotics with a complex septated 6.5 cm adnexal mass indicates a tubo-ovarian abscess, which requires admission, intravenous broad-spectrum antibiotics and ultrasound-guided or surgical drainage; oral therapy alone will fail.", "d": "Persistent fever on oral PID therapy + complex adnexal collection = tubo-ovarian abscess → IV antibiotics + drainage", "t": "Severity under-recognition — PID downgrade when an abscess is present", "f": "PID + persistent fever on oral therapy → scan for tubo-ovarian abscess → admit and drain", "r": "Tubo-ovarian abscess = IV antibiotics + drainage (percutaneous, transvaginal or surgical)", "x": [["A) Continue the oral antibiotic course at home", "More than 72 hours of fever on appropriate oral therapy defines outpatient failure — continuing the same course is unsafe with an abscess."], ["C) Add oral fluconazole to the current regimen", "Fluconazole treats fungal infection; there is no candida exposure in this picture — this delays definitive care."], ["D) Remove the intrauterine device and continue oral therapy at home", "IUD removal is considered in PID management but does not treat an established abscess; the patient needs admission and drainage."]]}, {"n": 45, "s": "A 20-year-old university student who is sexually active requests contraception. She often forgets daily pills, wants reliable protection for the next 3 years that she can stop at any time, and prefers to avoid anything inserted vaginally. Her blood pressure is 110/70 mmHg and BMI is 22 kg/m². She has no medical problems. Which contraceptive is most appropriate?", "o": [["A", "Etonogestrel subdermal implant"], ["B", "Combined oral contraceptive pill"], ["C", "Depot medroxyprogesterone acetate 3-monthly"], ["D", "Copper intrauterine device"]], "c": ["A)", "Etonogestrel subdermal implant"], "co": "Contraception — long-acting reversible method selection (subdermal implant)", "ct": "Analysis/synthesis (adherence, duration, and reversibility weighed)", "w": "The etonogestrel subdermal implant is the most effective reversible method that requires no daily adherence, lasts 3 years, can be removed at any time, and is not inserted vaginally — it is the LARC-first choice for this young woman.", "d": "Forgettable-pill user wanting ~3 years, fully reversible, non-vaginal → etonogestrel implant (LARC-first)", "t": "Treatment ladder — LARC before user-dependent methods in young women", "f": "Adherence concern + 3-year horizon + non-vaginal preference = implant, not pills or injections", "r": "Forgettable pills + long-acting reversible request = etonogestrel implant (most effective, removable, non-vaginal)", "x": [["B) Combined oral contraceptive pill", "The COC is user-dependent and requires daily adherence, which this patient has already failed."], ["C) Depot medroxyprogesterone acetate 3-monthly", "DMPA requires 12-weekly returns, has a delayed return of fertility, and carries weight and bone-density concerns."], ["D) Copper intrauterine device", "The copper IUD is highly effective but requires vaginal insertion and commits to a much longer duration than the 3 years she wants."]]}, {"n": 46, "s": "A 26-year-old woman with polycystic ovary syndrome (oligomenorrhea, hirsutism and acne; BMI 28 kg/m²) has only 3–4 periods a year. She is sexually active and requests contraception; she does not wish to conceive. Which management best protects her endometrium and addresses her symptoms?", "o": [["A", "Combined oral contraceptive"], ["B", "Metformin alone"], ["C", "Letrozole for ovulation induction"], ["D", "Ten-day courses of progestogen alone each month"]], "c": ["A)", "Combined oral contraceptive"], "co": "PCOS — endometrial protection and symptom control when not seeking pregnancy", "ct": "Interpretation (PCOS needs cycle control and endometrial cover)", "w": "Fewer than 4 periods a year exposes the endometrium to unopposed estrogen; the combined oral contraceptive restores cycles, protects the endometrium, treats hirsutism and acne, and provides contraception — comprehensively better than metformin or progestogen courses alone.", "d": "Infrequent menstruation in PCOS = unopposed estrogen; contraception + hirsutism + acne = COC, not metformin", "t": "Treatment misdirection — metformin chosen when the goal is endometrial protection", "f": "PCOS + contraception request + hyperandrogenism = COC first; metformin is for metabolic risk", "r": "PCOS + infrequent menses + contraception need = combined oral contraceptive (cycle control + endometrial protection)", "x": [["B) Metformin alone", "Metformin improves metabolic parameters but does not regulate cycles, protect the endometrium or provide contraception."], ["C) Letrozole for ovulation induction", "Letrozole is an ovulation-induction agent for women trying to conceive — this patient explicitly does not wish to conceive."], ["D) Ten-day courses of progestogen alone each month", "Cyclic progestogen gives some endometrial cover but provides no contraception and does not treat hirsutism or acne."]]}, {"n": 47, "s": "A 26-year-old nulliparous woman at 7 weeks of amenorrhea has mild brown spotting but no pain. Quantitative β-hCG fell from 850 to 610 IU/L over 48 hours. Transvaginal ultrasound shows an empty uterus and a 2.0 cm left adnexal mass without a fetal pole or free fluid. She is hemodynamically stable. What is the most appropriate management?", "o": [["A", "Expectant management with serial β-hCG"], ["B", "Single-dose methotrexate"], ["C", "Laparoscopic salpingectomy"], ["D", "Laparoscopic salpingotomy"]], "c": ["A)", "Expectant management with serial β-hCG"], "co": "Ectopic pregnancy — expectant management in spontaneous resolution", "ct": "Interpretation/Analysis (declining hCG points to the expectant pathway)", "w": "A falling β-hCG with a small (2 cm) ectopic mass, no fetal pole, no pain and no free fluid indicates a resolving ectopic pregnancy; expectant management with serial β-hCG is appropriate, reserving methotrexate for plateau or rising titers and surgery for instability.", "d": "Falling β-hCG + small mass + no symptoms + no free fluid = spontaneous resolution → expectant care with serial hCG", "t": "Treatment ladder — expectant before medical before surgical in ectopic", "f": "Ectopic + falling hCG = watch; plateau/rising hCG = methotrexate; instability/tubal rupture = surgery", "r": "Resolving ectopic (falling hCG, small mass, asymptomatic) = expectant management with serial β-hCG", "x": [["B) Single-dose methotrexate", "Methotrexate is used when hCG plateaus or rises; with a proven downward trend in an asymptomatic patient, medical therapy is not yet indicated."], ["C) Laparoscopic salpingectomy", "Salpingectomy is for rupture, instability or a non-viable tube — this patient is stable with resolving disease."], ["D) Laparoscopic salpingotomy", "Salpingotomy preserves the tube for future fertility but is reserved for cases needing surgery where tubal conservation is desired — not for spontaneous resolution."]]}, {"n": 48, "s": "A 26-year-old mother is exclusively breastfeeding her 5-month-old infant on demand and has been amenorrheic since delivery. She asks whether she still needs contraception. Which statement about the lactational amenorrhea method (LAM) is correct?", "o": [["A", "It remains reliable as long as any breastfeeding continues"], ["B", "It is reliable only when the mother is amenorrheic, exclusively breastfeeding, and within 6 months postpartum"], ["C", "It is reliable if the mother breastfeeds at least 6 times daily, regardless of menstrual status"], ["D", "It is the single most effective contraceptive method available"]], "c": ["B)", "It is reliable only when the mother is amenorrheic, exclusively breastfeeding, and within 6 months postpartum"], "co": "Contraception — lactational amenorrhea method criteria", "ct": "Recall (LAM requires all three criteria)", "w": "The lactational amenorrhea method is reliable only when all three criteria hold — amenorrhea, exclusive breastfeeding, and less than 6 months postpartum; once menstruation returns, supplementation begins, or the infant reaches 6 months, another method is needed.", "d": "LAM is effective only with ALL three: <6 months postpartum + exclusive breastfeeding + amenorrhea", "t": "Partial Truth — breastfeeding alone is not contraception; all three LAM criteria are required", "f": "LAM = amenorrhea + exclusive breastfeeding + <6 months; loses efficacy if any criterion fails", "r": "LAM reliable only if amenorrheic + exclusively breastfeeding + <6 months postpartum", "x": [["A) It remains reliable as long as any breastfeeding continues", "Breastfeeding is not contraception indefinitely — efficacy collapses beyond 6 months, with supplementation, or with return of menses."], ["C) It is reliable if the mother breastfeeds at least 6 times daily, regardless of menstrual status", "Frequency of feeds alone is insufficient; return of menstruation makes LAM unreliable even with frequent feeding."], ["D) It is the single most effective contraceptive method available", "LAM is not the most effective method (LARC methods exceed it); and it was not chosen here for efficacy comparisons."]]}, {"n": 49, "s": "A 42-year-old woman with regular cycles has had progressively heavy, painful periods for 3 years. Transvaginal ultrasound shows a diffusely and uniformly enlarged uterus with no focal mass. MRI shows thickening of the junctional zone to 14 mm. What is the most likely diagnosis?", "o": [["A", "Adenomyosis"], ["B", "Multiple uterine fibroids"], ["C", "Endometriosis"], ["D", "Endometrial hyperplasia"]], "c": ["A)", "Adenomyosis"], "co": "Adenomyosis — imaging diagnosis (junctional zone)", "ct": "Interpretation (junctional zone thickening on MRI)", "w": "A diffusely and uniformly enlarged uterus with a junctional zone of 14 mm (≥12 mm) on MRI is diagnostic of adenomyosis — the endometrial glands within the myometrium cause uniform enlargement, unlike the asymmetric focal masses of fibroids.", "d": "Uniform uterine enlargement + junctional zone ≥12 mm = adenomyosis; fibroids are focal/asymmetric", "t": "Pattern recognition — junctional zone ≥12 mm is the adenomyosis giveaway", "f": "Uniform enlargement + junctional zone ≥12 mm = adenomyosis; irregular/asymmetric enlargement = fibroids", "r": "Junctional zone ≥12 mm on MRI + diffuse uniform uterine enlargement = adenomyosis", "x": [["B) Multiple uterine fibroids", "Fibroids are well-circumscribed focal masses that enlarge the uterus asymmetrically and irregularly, not diffusely with junctional zone thickening."], ["C) Endometriosis", "Endometriosis is endometrial tissue outside the uterus (ovaries, peritoneum); it does not thicken the myometrial junctional zone."], ["D) Endometrial hyperplasia", "Endometrial hyperplasia causes abnormal bleeding without diffuse myometrial enlargement."]]}, {"n": 50, "s": "A 41-year-old woman presents with a 6-month history of pelvic pressure. Ultrasound shows an 11 cm solid, well-defined mass whose origin (uterine versus ovarian) cannot be determined. Which investigation best characterizes the origin and tissue type before surgery?", "o": [["A", "MRI of the pelvis"], ["B", "CT of the abdomen and pelvis"], ["C", "PET-CT"], ["D", "Immediate diagnostic laparoscopy"]], "c": ["A)", "MRI of the pelvis"], "co": "Pelvic mass differential — MRI for characterization of indeterminate origin", "ct": "Analysis/synthesis (US-indeterminate mass → best characterization tool)", "w": "When an ultrasound cannot assign a large solid pelvic mass to the uterus or ovary, MRI of the pelvis provides the best soft-tissue characterization — it identifies the organ of origin, tissue composition and invasion, guiding surgical planning.", "d": "Large solid pelvic mass of uncertain uterine/ovarian origin → MRI defines origin and tissue planes preoperatively", "t": "Investigation hierarchy — MRI characterizes what ultrasound cannot", "f": "Indeterminate large solid pelvic mass = MRI first (CT for staging cancer; laparoscopy is therapeutic, not diagnostic-first)", "r": "US-indeterminate solid pelvic mass = pelvic MRI for origin and tissue characterization", "x": [["B) CT of the abdomen and pelvis", "CT is excellent for staging known malignancy but has inferior soft-tissue contrast for distinguishing ovarian from uterine origin."], ["C) PET-CT", "PET-CT evaluates metabolic activity and recurrence, not the anatomic origin of an indeterminate mass."], ["D) Immediate diagnostic laparoscopy", "Diagnostic laparoscopy is invasive and planned only after imaging informs the approach; it is not the first characterization step."]]}, {"n": 51, "s": "During a difficult vertex delivery the fetal head delivers but the anterior shoulder is impacted behind the symphysis pubis; gentle downward traction fails. What is the first manoeuvre?", "o": [["A", "McRoberts position with suprapubic pressure"], ["B", "Fundal pressure"], ["C", "Immediate caesarean without moving the head"], ["D", "Zavanelli manoeuvre"]], "c": ["A)", "McRoberts position with suprapubic pressure"], "co": "Shoulder dystocia — McRoberts first", "ct": "Recall", "w": "Shoulder dystocia is an obstetric emergency managed by a structured sequence beginning with McRoberts manoeuvre (hyperflexion of thighs) and suprapubic pressure; fundal pressure is contraindicated because it further impacts the shoulder.", "d": "Shoulder dystocia: McRoberts + suprapubic pressure first; fundal pressure is contraindicated (worsens impaction)", "t": "Never-do trap — fundal pressure in shoulder dystocia", "f": "Shoulder dystocia sequence: McRoberts, suprapubic pressure, posterior arm, rotational manoeuvres (Woods), Zavanelli as last resort; NEVER fundal pressure.", "r": "Shoulder dystocia management: McRoberts + suprapubic pressure first; then internal rotation (Woods), posterior arm delivery, all-fours; document head-to-body interval; prepare neonatal resuscitation.", "x": [["B) Fundal pressure", "Fundal pressure is contraindicated and worsens impaction."], ["C) Immediate caesarean without moving the head", "The head is already delivered; caesarean is not an option until other manoeuvres and (rarely) Zavanelli replacement."], ["D) Zavanelli manoeuvre", "Zavanelli (cephalic replacement) is the last-resort manoeuvre."]]}, {"n": 52, "s": "A 28-year-old with two mid-trimester painless losses develops a ballooning fetal membranes bulge at 14 weeks with a closed cervix on speculum except the membranes. What is the management approach?", "o": [["A", "Cervical cerclage (history-indicated) ideally before 14–16 weeks"], ["B", "Bed rest only"], ["C", "Prophylactic tocolytics"], ["D", "Termination of pregnancy"]], "c": ["A)", "Cervical cerclage (history-indicated) ideally before 14–16 weeks"], "co": "Cervical incompetence — cerclage", "ct": "Interpretation", "w": "Cervical incompetence is suggested by recurrent painless mid-trimester losses and cervical shortening/membrane prolapse. History-indicated cerclage is placed at 12–14 weeks; in this scenario with membranes already bulging, physical-exam-indicated cerclage may still be attempted in selected cases, with alternatives like Arabin pessary.", "d": "Recurrent mid-trimester painless losses + bulging membranes = cervical incompetence; cerclage is the intervention", "t": "Timing trap — cerclage window", "f": "Recurrent mid-trimester painless loss = cervical incompetence; cerclage 12–14 weeks; rescue cerclage if membranes not infected.", "r": "Cervical incompetence: history/ultrasound/exam-indicated cerclage; exclude infection and PPROM before rescue cerclage; progesterone support.", "x": [["B) Bed rest only", "Bed rest has no proven benefit in cervical incompetence."], ["C) Prophylactic tocolytics", "Tocolytics do not treat mechanical cervical incompetence."], ["D) Termination of pregnancy", "Termination is not indicated for a viable fetus at 14 weeks."]]}, {"n": 53, "s": "During active labour a multiparous woman suddenly collapses with dyspnoea, cyanosis, hypotension and then profuse vaginal bleeding with coagulopathy. What is the most likely diagnosis?", "o": [["A", "Amniotic fluid embolism"], ["B", "Uterine rupture"], ["C", "Placental abruption"], ["D", "Pulmonary embolism"]], "c": ["A)", "Amniotic fluid embolism"], "co": "Amniotic fluid embolism", "ct": "Interpretation", "w": "Amniotic fluid embolism presents with sudden cardiovascular collapse, hypoxia and coagulopathy during labour or shortly after delivery. It is largely a clinical diagnosis and managed supportively with oxygenation, fluids, inotropes, and correction of DIC.", "d": "Sudden peripartum collapse + hypoxia + DIC = amniotic fluid embolism; classic but catastrophic presentation", "t": "Catastrophic-event recognition trap", "f": "Sudden intrapartum collapse + hypoxia + DIC = AFE; supportive multiorgan care; consider uterine tone causes if bleeding dominates.", "r": "AFE: sudden collapse, hypoxia, DIC, hypotension in labour/postpartum; supportive: airway, circulation, coagulation products; high mortality.", "x": [["B) Uterine rupture", "Uterine rupture causes pain, haemorrhage and fetal distress, without the primary respiratory/collapse picture."], ["C) Placental abruption", "Abruption is antepartum bleeding with pain and fetal distress."], ["D) Pulmonary embolism", "PE causes hypoxia, but DIC and peripartum timing point to AFE."]]}, {"n": 54, "s": "A 39-year-old woman with heavy menstrual bleeding has an ultrasound showing a 3-cm submucosal fibroid. She has completed childbearing. What is the most appropriate management?", "o": [["A", "Hysteroscopic myomectomy or levonorgestrel IUD as symptom-directed options"], ["B", "Hysterectomy for all fibroids"], ["C", "Observation alone, ignoring symptoms"], ["D", "Immediate GnRH agonist monotherapy for life"]], "c": ["A)", "Hysteroscopic myomectomy or levonorgestrel IUD as symptom-directed options"], "co": "Fibroid symptom-directed management", "ct": "Interpretation", "w": "Submucosal fibroids are the most likely to cause heavy menstrual bleeding. Surgical options include hysteroscopic myomectomy (resectable), or LNG-IUS for symptom control; hysterectomy is only for refractory symptoms or after failed conservative treatment, not automatic.", "d": "Submucosal fibroid causing HMB in a woman done with childbearing: hysteroscopic myomectomy or LNG-IUD; choice by symptom burden and preference", "t": "Over-treatment trap", "f": "Submucosal fibroid + HMB: hysteroscopic myomectomy / LNG-IUD; hysterectomy only if refractory.", "r": "Fibroid management is symptom-directed: asymptomatic = observe; HMB = medical (LNG-IUS, tranexamic) or myomectomy; completed childbearing + failure = hysterectomy options.", "x": [["B) Hysterectomy for all fibroids", "Hysterectomy is not required for all fibroids; conservative options are effective."], ["C) Observation alone, ignoring symptoms", "Heavy menstrual bleeding warrants treatment, not ignoring."], ["D) Immediate GnRH agonist monotherapy for life", "GnRH agonists are short-term pre-operative adjuncts, not lifelong monotherapy."]]}, {"n": 55, "s": "A 34-week primigravida with severe preeclampsia on labetalol develops epigastric pain, vomiting, transaminitis (ALT 350), platelet count 60, and elevated LDH with fragmented red cells on smear. What is the diagnosis and plan?", "o": [["A", "HELLP syndrome - stabilise and deliver after corticosteroids for fetal lung maturity"], ["B", "Hyperemesis gravidarum - fluids only"], ["C", "Acute fatty liver of pregnancy - wait until term"], ["D", "Gallstone pancreatitis - conservative care"]], "c": ["A)", "HELLP syndrome - stabilise and deliver after corticosteroids for fetal lung maturity"], "co": "HELLP syndrome - delivery planning", "ct": "Interpretation", "w": "HELLP syndrome (haemolysis, elevated liver enzymes, low platelets) is a severe form of preeclampsia. Management is maternal stabilisation (antihypertensives, magnesium sulfate seizure prophylaxis, corticosteroids for fetal lung maturity if <34-36 weeks) and delivery.", "d": "Preeclampsia + haemolysis (LDH/fragmented cells) + elevated liver enzymes + low platelets = HELLP; definitive therapy is delivery", "t": "Complication-recognition trap", "f": "Preeclampsia + epigastric pain + low platelets + raised LFTs = HELLP; delivery is definitive.", "r": "HELLP: thrombocytopenia, haemolysis (LDH, schistocytes), transaminitis in preeclampsia; manage BP, magnesium, steroids, and deliver according to gestational age and maternal stability.", "x": [["B) Hyperemesis gravidarum - fluids only", "Hyperemesis is first-trimester vomiting, not third-trimester epigastric pain with this laboratory picture."], ["C) Acute fatty liver of pregnancy - wait until term", "Acute fatty liver of pregnancy has hypoglycaemia and coagulopathy but also demands delivery, not waiting."], ["D) Gallstone pancreatitis - conservative care", "Gallstone pancreatitis would show a different laboratory pattern (amylase/lipase) and imaging."]]}, {"n": 56, "s": "A breastfeeding woman on day 20 postpartum has a tender, swollen, erythematous left breast with fever 38.6 C. Milk culture grows Staphylococcus aureus. What is the next step?", "o": [["A", "Continue breastfeeding and start flucloxacillin; add drainage if an abscess develops"], ["B", "Stop breastfeeding and give metronidazole"], ["C", "Cold compresses only"], ["D", "Immediate incision and drainage"]], "c": ["A)", "Continue breastfeeding and start flucloxacillin; add drainage if an abscess develops"], "co": "Lactational mastitis - continue feeding + antibiotics", "ct": "Interpretation", "w": "Lactational mastitis is usually staphylococcal; management is continued breastfeeding or expression (empties the breast), analgesia, and an antistaphylococcal antibiotic such as flucloxacillin. If a fluctuant abscess develops, ultrasound-guided aspiration or incision and drainage is added.", "d": "Mastitis (S. aureus) = continue breastfeeding + flucloxacillin; only abscess needs surgical drainage", "t": "Continue-vs-stop feeding trap", "f": "Mastitis: KEEP breastfeeding, flucloxacillin; abscess -> ultrasound + drainage.", "r": "Mastitis: continue breastfeeding, flucloxacillin (or alternative in penicillin allergy), supportive measures; abscess requires drainage.", "x": [["B) Stop breastfeeding and give metronidazole", "Stopping breastfeeding worsens engorgement; metronidazole does not cover staphylococci."], ["C) Cold compresses only", "Cold compresses are adjunctive; antibiotics are required for a systemic febrile infection."], ["D) Immediate incision and drainage", "Incision and drainage is only for abscess; uncomplicated mastitis is managed medically."]]}, {"n": 57, "s": "A 32-year-old with polycystic ovary syndrome (irregular menses, acne, elevated free androgen index) and body mass index 32 asks about long-term health. Her glucose tolerance test is normal. What is the most important non-fertility counselling point?", "o": [["A", "Lifelong metabolic surveillance: type 2 diabetes, metabolic syndrome and cardiovascular risk reduction through weight loss and lifestyle"], ["B", "She will definitely develop endometrial cancer"], ["C", "No long-term risk exists once menses are regular"], ["D", "Metformin is mandatory regardless of glucose"]], "c": ["A)", "Lifelong metabolic surveillance: type 2 diabetes, metabolic syndrome and cardiovascular risk reduction through weight loss and lifestyle"], "co": "PCOS long-term metabolic consequences", "ct": "Analysis/Synthesis", "w": "PCOS confers lifelong increased risk of type 2 diabetes, metabolic syndrome, cardiovascular risk factors, and endometrial hyperplasia/carcinoma from chronic anovulation with unopposed oestrogen. The mainstay is weight loss, lifestyle modification, and periodic metabolic screening, plus cycle regulation.", "d": "PCOS: increased long-term type 2 diabetes, metabolic syndrome, CVD risk factors, and endometrial hyperplasia from unopposed estrogen - lifestyle-first counselling", "t": "Long-term-risk minimisation trap", "f": "PCOS counselling: T2DM/HTN/CVD risk, endometrial cancer risk, OSA; lifestyle + metformin when insulin-resistant; cycle regulation to protect endometrium.", "r": "PCOS (Rotterdam: 2 of 3 = oligo-anovulation, hyperandrogenism, polycystic ovaries): screen for metabolic syndrome, T2DM, NAFLD; regulate cycles (OCP, progestins) to prevent endometrial hyperplasia; metformin for insulin resistance.", "x": [["B) She will definitely develop endometrial cancer", "Risk is increased but not certain; counselling should be risk-based, not deterministic."], ["C) No long-term risk exists once menses are regular", "Even with regular menses induced by treatment, underlying metabolic risk persists."], ["D) Metformin is mandatory regardless of glucose", "Metformin is indicated for insulin resistance/glucose abnormality, not mandatory in every PCOS patient."]]}, {"n": 58, "s": "A 34-week primigravida has severe generalised pruritus worse at night, with no rash. LFTs are normal but fasting bile acids are 45 µmol/L. Which fetal risk does this pose and what is the key intervention?", "o": [["A", "Intrahepatic cholestasis of pregnancy — risk of stillbirth; ursodeoxycholic acid and planned delivery by term"], ["B", "HELPP syndrome — urgent caesarean"], ["C", "Allergic urticaria — antihistamines"], ["D", "Viral hepatitis — antivirals"]], "c": ["A)", "Intrahepatic cholestasis of pregnancy — risk of stillbirth; ursodeoxycholic acid and planned delivery by term"], "co": "Intrahepatic cholestasis of pregnancy", "ct": "Interpretation", "w": "Intrahepatic cholestasis of pregnancy presents with intense pruritus and elevated fasting bile acids. Level ≥40 µmol/L increases the risk of fetal demise; treatment is ursodeoxycholic acid with planned delivery near term and fetal surveillance.", "d": "Pruritus + raised bile acids + normal LFTs = ICP; bile acids ≥40 µM correlate with stillbirth risk; UDCA and early delivery at 36–39 weeks", "t": "Number trap — bile acid threshold", "f": "ICP: bile acids ≥40 µmol/L = higher stillbirth risk; UDCA, serial bile acids, deliver 36–39 weeks.", "r": "ICP: pruritus + bile acids ≥10 µmol/L; ≥40 µM = increased risk; UDCA; plan delivery by 36–39 weeks depending on bile acid levels.", "x": [["B) HELPP syndrome — urgent caesarean", "HELLP is haemolysis/elevated LFTs/low platelets with hypertension — not isolated pruritus."], ["C) Allergic urticaria — antihistamines", "The absence of rash with elevated bile acids defines ICP, not urticaria."], ["D) Viral hepatitis — antivirals", "Viral hepatitis shows marked transaminitis and jaundice, not isolated pruritus."]]}, {"n": 59, "s": "A 26-year-old completes suction evacuation for a complete hydatidiform mole. Histology confirms molar pregnancy. What is the follow-up plan?", "o": [["A", "Serial serum beta-hCG weekly until negative, then monthly for 6-12 months; reliable contraception"], ["B", "No follow-up needed"], ["C", "Hysterectomy for all patients"], ["D", "Chemotherapy for all patients"]], "c": ["A)", "Serial serum beta-hCG weekly until negative, then monthly for 6-12 months; reliable contraception"], "co": "Molar pregnancy surveillance", "ct": "Recall", "w": "After molar evacuation, beta-hCG is monitored weekly until negative for 3 weeks, then monthly until negative for 6-12 months to detect persistent gestational trophoblastic neoplasia (which may need chemotherapy). Reliable contraception avoids confounding rising hCG from pregnancy.", "d": "Post-molar surveillance: weekly serum beta-hCG until undetectable, then monthly; monitor for gestational trophoblastic neoplasia", "t": "Number trap - surveillance frequency", "f": "Molar follow-up: weekly beta-hCG then monthly x6-12; rising/plateauing hCG = GTN -> methotrexate.", "r": "Complete mole: suction curettage, histology, weekly beta-hCG until negative, then monthly 6-12 months, contraception; treat persistent disease with chemotherapy.", "x": [["B) No follow-up needed", "Without surveillance, persistent trophoblastic disease (choriocarcinoma) can be missed."], ["C) Hysterectomy for all patients", "Hysterectomy is reserved for selected non-childbearing or refractory cases, not routine."], ["D) Chemotherapy for all patients", "Chemotherapy is only for persistent or metastatic disease, not all moles."]]}, {"n": 60, "s": "A 30-year-old primigravida delivers vaginally; 20 minutes later heavy bleeding begins. The uterus is boggy despite massage and oxytocin infusion, and she is hypertensive from preeclampsia. What is the next most appropriate uterotonic?", "o": [["A", "Ergometrine"], ["B", "Carboprost (15-methyl PGF2α)"], ["C", "Tranexamic acid alone"], ["D", "Reassess in 30 minutes"]], "c": ["B)", "Carboprost (15-methyl PGF2α)"], "co": "PPH atony drug sequencing — contraindication-adjusted", "ct": "Analysis/Synthesis", "w": "In postpartum haemorrhage from uterine atony unresponsive to oxytocin, second-line uterotonics include ergometrine and carboprost. Ergometrine is contraindicated in hypertension (preeclampsia) because of vasoconstriction, so carboprost is the correct next agent.", "d": "Boggy uterus on oxytocin = second-line uterotonic; ergometrine contraindicated in hypertension; carboprost is the choice (avoid in asthma)", "t": "Contraindication trap in drug selection", "f": "PPH atony ladder: oxytocin → ergometrine (not in HTN) / carboprost (not in asthma) → misoprostol → balloon/compression sutures → hysterectomy.", "r": "PPH atony: massage + oxytocin; ergometrine (avoid in hypertension, preeclampsia), carboprost (avoid in asthma), misoprostol; escalate to intrauterine balloon, B-Lynch, hysterectomy.", "x": [["A) Ergometrine", "Ergometrine is contraindicated in hypertensive/preeclamptic patients due to vasoconstriction."], ["C) Tranexamic acid alone", "Tranexamic acid is adjunctive (WOMAN trial) and does not replace a second-line uterotonic."], ["D) Reassess in 30 minutes", "Delaying intervention in ongoing PPH risks shock and coagulopathy."]]}], "c": 60}}

Test Series 2026